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Zusammenfassung 
Telomere befinden sich an den Enden der linearen Chromosomen um das Genom zu schützen und zu 
stabilisieren. Ein Telomere besteht aus TTAGGG-Wiederholungen von DNA Sequenzen. Erst kürzlich 
wurde gezeigt, dass Telomere in TERRA (Telomere repeat containing RNA) umgeschrieben werden. 
Diese nicht-kodierenden RNAs spielen eine Rolle für Telomere erhaltenden Mechanismen (TMM) 
und für die Organisation von Chromatin. Die Transkription von TERRA startet im Bereich der 
Subtelomere und hängt vom epigenetischen Zustand der Telomere ab. Astrozytome verwenden zwei 
TMM, einerseits Telomeraseaktivität (TA) und andererseits einen alternativen Mechanismus (ALT = 
alternative lengthening of telomeres).Der ALT-Mechanismus führt in der Regel zu längeren 
Telomeren als der TA-Mechanismus. Eine Korrelation zwischen TMM und dem Überleben von 
Patienten wurde für hochgradige Astrozytome gefunden, wie für Glioblastoma multiforme (GBM). 
Diese Erkenntnis und die schlechte Prognose für Patienten mit GBM führen zur Notwendigkeit der 
weiteren Charakterisierung von TERRA in diesen Tumoren. 
In dieser Studie wurden Tumor-Gewebeproben (ts) von 46 Patienten mit Diagnosen Astrozytome 
WHO-Grad II bis IV untersucht: 12 diffuse Astrozytome (DA) Grad II, 6 anaplastische Astrozytome 
(AA) Grad III und 28 GBM Grad IV. Ergänzend wurden Tumor-Zelllinien untersucht, 12 etabliert aus 
Astrozytome und eine ALT-Zelllinie aus einem primären Osteosarkom. RNA und DNA wurden 
isoliert. Um die Relative Menge (RQ) der Transkriptionslevels zu messen, wurde die RNA in DNA 
umgeschrieben und eine Real Time PCR durchgeführt. Expressionslevel wurden mit jenen der house-
keeping Gene Beta-Aktin und 36B4 verglichen. Die Telomerlänge wurde mit TRF Analyse und Real-
time PCR bestimmt. Relative Mengen wurden zwischen den untersuchten Gruppen mit dem Mann-
Whitney-Test verglichen. Nach logarithmischer Transfromierung der RQ-Werte wurde eine Pearson 
Korrelation durchgeführt. Von 12 Tumorproben wurde der epigenetische Status der Subtelomere für 
das Chromosom 2p durch Bisulfit-Sequenzierung bestimmt.  
Die Expression aller TERRA Moleküle war um das 14 und 31-fache bei GBM niedriger verglichen 
mit jeweils AA-und DA (p <0,05). Zelllinien der Astrozytome zeigen TERRA Expression 
vergleichbar wie bei GBM, im Gegensatz dazu zeigt die ALT-Zelllinie ähnliche Expression wie bei 
DA. Chromosom 2p-und 18p-TERRA Expression ändert sich nicht signifikant mit dem Tumorgrad. 
Die durchschnittliche Telomerlänge war bei niedriggradigen Tumoren DA (22 ± 15 kbp) und AA (17 
± 5 kbp) deutlich erhöht, verglichen mit GBM (9 ± 4 kbp). Die gesamte TERRA Expression korreliert 
mit der Telomerlänge (Pearson-Koeffizient P = 0,38, p = 0,01). Tumor Proben zeigen Unterschiede 
der Durchschnittswerte der CpG-Methylierung im 2pTERRA-Promotor von 89% und 83% bei jeweils 
niedrigen und hohen 2p-TERRA Expressionswerten. Erste Analysen zeigen einen signifikanten 
Zusammenhang zwischen dem Überleben der Patienten und der gefundenen TERRA Expression. 
Niedrige Expression von TERRA korreliert mit einer schlechten Prognose. 
Die relative Expression von TERRA korrelliert in astrozytären Tumoren signifikant mit der 
Telomerelänge, mit dem Tumorgrad und dem Methylierungsstatus des Promotors. Die relative 
TERRA Expression könnte ein vielversprechender Kandidat als diagnostischer und prognostischer 
Marker bei astrozytären Tumoren sein. 
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1 Abstract 
Telomeres are localized at chromosomal ends to protect and stabilize the whole genome from 
deterioration. A telomere consists of TTAGGG repeat DNA sequences. It has been shown 
recently, that telomeres are transcribed into telomeric repeat-containing RNA (TERRA) 
involved in telomere maintenance mechanisms (TMM) and chromatin organization. TERRA 
transcription originates in the subtelomere and depends on the epigenetic state of the 
telomere. Astrocytomas utilize two TMM based on telomerase activity (TA) and on 
alternative lengthening of telomeres (ALT). ALT results telomeres longer than TA 
mechanism. Correlation between TMM and patient survival was demonstrated for high grade 
astrocytomas, especially glioblastoma multiforme (GBM). This finding and dismal prognosis 
of patients suffering from GBM emphasizes the need for detailed characterization of telomere 
length and TERRA in these tumors.  
A panel of tumor tissue samples (ts) were analyzed which originated from 46 patients with 
diagnoses astrocytomas WHO grade II to IV: 12 diffuse astrocytomas (DA) grade II, 6 
anaplastic astrocytomas (AA) grade III and 28 GBM grade IV. Further, human tumor cell 
lines were analyzed, 12 originated from astrocytomas and one ALT cell line from an 
osteosarcoma. RNA and DNA were isolated. Relative quantities (RQ) of transcript expression 
levels for overall and chromosome-specific TERRA were measured by reverse transcription 
following real-time PCR and compared to beta actin and 36B4 levels. Telomere length was 
determined by TRF Southern blotting and real-time PCR. RQs were compared between 
groups by Mann-Whitney test and log-transformed for Pearson correlation calculation. 
Epigenetic state of subtelomeric region for chromosome 2p was determined by bisulphite 
allelic sequencing of 12 ts. 
Overall TERRA expression was decreased 14 and 31-fold in GBM compared to AA and DA 
(p<0.05), respectively. Astrocytoma cell lines contained TERRA levels found as in GBM, the 
ALT cell line as in DA. Chromosome 2p- and 18p-TERRA expression was not significantly 
altered by grade. Mean telomere length was significantly increased in low grade tumors DA 
(22±15 kbp) and AA (17±5 kbp) as compared to GBM (9±4 kbp). Overall TERRA expression 
correlates with telomere length (Pearson’s coefficient P=0.38; p=0.01). Tumor samples with 
low and high 2p-TERRA expression levels demonstrate different average CpG methylation at 
2p-TERRA promoter of 89% and 83%, respectively. Primary analysis of expression and 
survival data indicates a significant connection of overall survival and expression of TERRA. 
Low TERRA levels correlate with a poor prognosis.  
Resulting data demonstrate that TERRA levels are in astrocytomas significantly related to 
telomere length, tumor grade and to promoter methylation status. Expression levels of 
TERRA can be considered promising candidates as diagnostic and potentially prognostic 
markers in astrocytomas. 
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2 Introductions 
 
2.1 Glioblastoma multiforme 
 
2.1.1 Gliomas 
 
Gliomas are a group of central nervous system (CNS) neoplasms with distinct histologic 
characteristics, comprising almost 60% of total human CNS malignancies. The common 
forms of gliomas in humans are astrocytomas, and the most aggressive form of astrocytomas 
is glioblastom multiforme (GBM) with histological signs of neoangiogenesis (Figure 2.1). 
GBMs are the most common form of malignant brain tumours in adults and it is also the most 
deadly one. The median life expectancy is about twelve month and only less than 5% of 
patients are still alive five years after diagnosis. The biology of gliomas is unique. Systematic 
metastasis occurs, but is very rare in this type of tumours. The majority of glioblastomas recur 
within two centimetres of their original tumour margin. They are very aggressive and 
frequently have been referred to as “whole-brain” or “whole-CNS” disease and a total 
resection almost always failed.[3] 
Malignancy grade is a prognostic factor for gliomas, although biological behaviour of gliomas 
of same grade is not always predictable. The period of survival and the choice of treatment 
depend on the malignancy grade. [2] 
Astrocytomas are found in young adulthood, but have a peak incidence in the third and fourth 
decade of life [4]. 
 
Figure 2.1 Vascular 
proliferation in 
glioblastoma 
multiforme [2] 
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Gliomas are classified into  
• astrocytomas,  
• oligodendrogliomas,  
• oligostrocytomas and  
• ependyomas (see table 2.1)  
 
based on the presumed cell of origin. They are further classified according to their degree of 
malignancy. High grade gliomas can manifest de novo (primary) or develop from a previous 
low grade tumour (secondary) (Fig. 2.2). About two thirds of the low grade gliomas progress 
to high grade tumours [2]. Seventy percent of grade II gliomas transform into grade III and IV 
tumours within 5 – 10 years. [5] 
 
Figure 2.2 Two pathways to GBM GBM can develop over 5 to 10 years from low-grade astrocytomas 
(secondary GBM), or it can be the initial pathology at diagnosis (primary GBM). [5] 
 
 
2.1.2 WHO grading system 
 
There are different grading systems applied for astrocytomas. One widely used system is the 
World health organisation (WHO) system. The main histological signs of malignancy in this 
system are nuclear atipia, mitotic activity, vascular proliferation and necrosis (see table 2.2). 
Presence of mitotic activity stands for poor prognosis of these tumours. Accurate pathological 
grading is essential because it defines treatment and prognosis. The histological features of 
the tumour and patients age are major prognostic factors and have more influence than any 
specific therapy on the outcome. 
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Table 2.1 Glial tumour classification, incidence, patient age and survival [2] 
Figure 2.3 Magnet 
resonance image (MRI) of 
low grade astrocytoma 
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The distinction between an anaplastic astrocytoma (grade III) and glioblastoma multiforme 
(grade IV) depends on the  
• microvascualar proliferation or 
• tumour necrosis 
 
In addition, many cases of GBM arise by a different genetic pathway than anaplastic 
astrocytomas. GBMs are largely a disease of adults, although cases in children are also 
known. The incidence of GBM increases with age and is highest at age of 65 to 75 years, and 
than it declines. Men are affected more commonly than women with a ration of 1.6:1 
 
Table 2.2 Grading systems for astrocytic gliomas [2] 
 
• Grade I tumours are biologically benign and can be surgically cured- 
• Grade II tumours are low-grade malignancies that may follow long clinical courses but 
are not curable by surgery.  
• Grade III tumours are malignant and lead to death within a few years. 
• Grade IV tumours are highly malignant, usually recalcitrant to chemotherapy and 
lethal within 9-12 months. Standard therapy at the AKH Vienna is surgery with 
concomitant chemo- and radiotherapy with akylating agents (1995-2000 CCNU or 
fotemustine/dacarbacine) and since 2000 Temozolamide (personal communication C. 
Marosi) 
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The central nervous system (CNS) consists of two major cell types:  
• neurons and  
• glia 
The latter are subdivided into three subpopulations: 
• astrocytes 
• oligodendrocytes 
• microglia 
 
Astrocytes are the most abundant type of glia cells in the CNS and provide growth factors for 
neurons. They have some very important functions, for example supporting and protecting 
neurons, inducing neurogenesis, regulating synapse formation and they initiate immune 
responses.  
 
Oligodendrocytes synthesize myelin in the CNS and also provide growth factors for neurons. 
A subgroup of gliomas is characterized as astrocytomas because the neoplastic cells show 
morphological characteristics of astrocytes. These tumours express differentiation markers of 
astrocytes, such as intermediate-filament glial fibrillary acid protein (GFAP) and calcium 
binding protein S100ß. This makes them different from the other main subgroup of gliomas, 
the oligodendrogliomas and makes a connection between normal glial differentiation and glial 
malignancy. 
 
Progenitor cells and malignant cells share some common features: simplicity in morphology, 
extended proliferation capacity, potential to differentiate and ability to migrate over longer 
distances. It is a widely accepted idea, that malignancy represents an undifferentiated state of 
their cellular origins. Progenitor and malignant cells share some characteristics. Both show a 
simplicity in their morphology, extended proliferation capacity, the ability to migrate over 
longer distances and the potential to differentiate [3].  
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2.1.3 Molecular genetic changes 
Figure 2.4 Molecular genetic changes in astrocytic brain tumours [2] 
p53, p16, PTEN ….tumour suppressors 
EGFR … epidermal growth factor receptor 
RB … retinoblastoma protein 
PDGF … platelet derived growth factor 
PDGFR … platelet derived growth factor receptor 
MDM2 … negative regulator of p53 tumour suppressor 
LOH … loss of heterozygosity 
 
Diffuse astrocytoma WHO grade II progress to anaplastic astrocytoma and glioblastoma, 
genetic changes occur which are often different from the changes found in a primary (de 
novo) glioblastoma. The genetic changes are shown in Figure 2.4 
It could be shown, that younger age is significantly correlated with a better outcome. Among 
molecular parameters, TP53 mutations predict a favourable clinical course independent of 
patient age and primary or secondary GBM status. LOH10q in GBM is associated with poor 
survival. Loss of either LOH1p or LOH19q has no prognostic significance in GBMs, but the 
combined loss of both of the two chromosomal arms may identify a patient group with better 
prognosis and potentially sensitive to chemotherapy. Loss of LOH19 is found in both, 
primary and secondary GBMs, but shows a tendency to be more common in primary GBMs 
[6]. 
 13 
2.2 Telomeres 
 
2.2.1 Structure and function of telomeres  
 
Telomeres protect the chromosomal ends from being recognized by DNA repair mechanism 
as double strand breaks, they prevent them from chromosomal end fusion and degradation. In 
this way they maintain the stability of the linear chromosomes. 
They were first described by Hermann Muller in the fruit fly Drosophila melanogaster. He 
was the first to coin the term “telomere” in 1938. He predicted that telomeres must have a 
special function in sealing the ends of chromosomes. A chromosome could not persist 
indefinitely without telomeres. [7] 
Figure 2.5 Telomeres are located at the ends of the linear chromosomes and consists of TTAGGG repeats 
in human [8] 
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Telomeric DNA sequences are very similar among otherwise widely divergent eukaryotes. 
The essential telomeric DNA consists of a stretch of very simple tandem repeated sequences. 
Chromosomal ends, the telomeres, are composed of thousands of repeats of a short 6 base pair 
(bp) sequence element. For vertebrates, for example, telomeric sequences consists of 
TTAGGG repeats (Figure 2.5 and 2.6) [9]. 
 
Figure 2.6 Organization of eukaryotic telomeres. Telomeres consist of repetitive telomeric sequences with 
single-stranded 3´ overhangs. Subtelomeric regions are composed of various short satellite-like repeats and 
middle-repetitive elements, interspersed with telomeric repeats. [10] 
 
The G-tail is protected by the so-called shelterin complex, consisting of 6 proteins. The 
telomeric repeat binding factor 1 (TRF1) and 2 (TRF2), which bind double stranded parts of 
the telomeric DNA. The telomere – shelterin complex forms two internal loops, the D-loop 
and the T-loop (Figure 2.7). POT1, another protein of the shelterin complex is binding the 
single stranded part of the telomeres and is suggested to be important for forming the D-loop. 
This complex protects the telomere from erosion and end-to-end fusion. Beside this 3 DNA-
binding proteins the telomere shelterin complex contains other proteins, like repressor 
activator protein 1 (Rap1), TPP1 and TRF1-interacting nuclear factor 2 (TIN2). Telomere 
shortening results in chromosome destabilization and inability to recruit proteins of the 
shelterin complex. The T-loop can not be formed and chromosome ends get uncapped. This 
leads to double strand breaks and may lead to inactivation of the p53 and p16/Ink4a pathway 
and may result in senescence or apoptosis[8]. 
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Figure 2.7 Formation of telomere loops. The single-stranded 3´-overhang of the very ends of telomeres invades 
upstream double-stranded telomeric sequences and hybridizes to complementary sequences, thereby forming a 
displacement loop (D-loop). TRF2 is supposed to stabilize this structure. Telomeric DNA loops out and might 
be stabilized by TRF1 proteins. [10] 
 
50 – 100 bp of telomere sequences are lost with every cell cycle form every chromosomal 
end, due to the end-replication problem (Figure 2.8). The inability of DNA polymerase to 
replicate the 3´-ends of chromosomal DNA leads to this gradually shortening and causes the 
loss of ability of telomeres, to protect the chromosomal ends. These unprotected ends take 
part in end-to-end chromosomal fusion, leading to crisis and death of the cells.  
 
Figure 2.6 End replication problem. DNA replication by the conventional polymerase proceeds in the 5´-to-3´ 
direction. The newly synthesized leading strands would not generate overhangs, but the newly synthesized 
lagging strands would lose their extreme 3´ end after RNA primers are removed. In addition, both parental 
strands might also be subject to nuclease processing. [11] 
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2.2.2 Maintaining of telomeres 
 
Almost all types of malignant cells maintain their telomeres by telomere-maintaining 
mechanisms. 85 – 90 % of them maintain their telomeres by the enzyme telomerase, a 
ribonuclear protein complex consisting of an RNA moiety (hTR or alternatively termed 
hTERC) which serves as template for telomeric repeats, and the catalytic subunit (hTERT) 
which has a reverse transcriptase function. The telomerase-negative remaining malignant cells 
have invented mechanisms, termed alternative lengthening of telomeres (ALT), which is 
based on recombination events leading to interchromosomal exchanges of sequence 
information. Both mechanisms are strongly suppressed in most of normal somatic human 
cells, to prevent a unlimited replicative potential and immortality [12]. 
 
2.2.3 Dysfunction of telomeres 
 
Telomeres can become dysfunctional through a variety of mechanisms. The most common is 
shortening due to the end-replication problem. The 3´- end of linear chromosomes cannot be 
completely replicated (Figure 2.8). So, telomeres get shorter with every replication cycle. 
When they become critically short, they fail to cap and protect the chromosome ends, leading 
to replicative senescence or apoptosis [13]. Telomeres can also loose function as a result of 
direct damage mainly by cellular stress, e.g. they are susceptible to oxidative DNA damage, 
which is a major source of DNA damage in mammalian cells [14]. 
Mutations that alter expression or function of telomere-associated proteins can also cause the 
dysfunction of telomeres. 
 
2.2.4 DNA damage response 
 
Dysfunctional telomeres are sensed as DNA contains a double strand break (DSB). So, they 
induce a classic DNA DSB response. These telomeres are marked by gamma-H2AX and a 
variety of other DNA damage response proteins, and are so similar or identical to unrepaired 
DNA breaks[15]. Dysfunctional telomeres, similar to irreparable DNA damage, are for a 
organism a great risk for developing cancer. They elicit cellular tumour suppressor 
mechanisms like apoptosis and senescence. Whether cells undergo apoptosis or senescence 
depends on cell type and genetic background, for example the p53 status of cells. Apoptosis 
eliminates cells, and senescence arrests their growth permanently [16]. 
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Both are controlled by p53 tumour suppressor protein. p53 is a transcriptional regulator that 
activates or represses genes in response to stress [17]. These p53 target genes stimulate DNA 
repair, transient or permanent cell cycle arrest (senescence) or cell death (apoptosis), 
depending on cell type, degree and type of damage. Cells that lack normal p53 regulation or 
function show a tendency to die in response to telomere dysfunction. Some normal human 
cells, on the other hand, undergo a senescence growth arrest. In either case, if present, p53 is 
essential for mediating the cellular response to telomere dysfunction [18].  
 
2.2.5 Impact of telomeres on cancer 
 
Cellular tumour suppressor mechanisms ensure that cells with telomere dysfunction can not 
divide. Cells that have lost these mechanisms of apoptosis and senescence, for example owing 
to mutations in p53 pathway and develop dysfunctional telomeres are at a great risk for 
neoplastic transformations. Even cells that have lost p53 must acquire a way to stabilize 
telomeres and so prevent loss of genetic information. Most frequently is this achieved by 
expression of telomerase, but there exist alternative pathways like ALT [19]. Telomeres can 
so both suppress and facilitate cancer.  
Summing up, functional telomeres are essential for prevention of genomic instability 
(Fig.2.9). By loosing telomeres, the cellular tumour suppressor mechanisms apoptosis and 
senescence are engaged. These responses prevent cells with dysfunctional telomeres from cell 
division to reduce the risk of cancer.  
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Figure 2.9 The outcome of telomere dysfunction includes the generation of a DNA damage signal. The fate 
of cells showing this signal, senescence or apoptosis, depends on p53. This cell fate influences the organism 
phenotypes of cancer and aging [13]. 
 
2.3 Expression of telomeres 
 
2.3.1 Telomeric repeat containing RNA (TERRA) 
Historically based on chromosome staining methods, telomeres could be classified as non-
transcribed heterochromatin. They are enriched in heterochromatin marks like: 
 
• trimethylation at lysine 9 on histone H3 
• trimethylation at lysine 20 on histone H4 and 
• HP1 (Heterochromatinprotein 1) 
 
The heterochromatic state, the geneless nature of telomeres, and the fact, that experimentally 
inserted reporter genes to the subtelomeric region led to the idea of transcriptionally silent 
telomeres.  
Contrary to the idea, of telomeres being silent genomic regions, recently it has been 
discovered that mammalian telomeres are transcribed by RNA polymerase II into TElomeric 
Repeat containing RNA (TERRA) molecules, which represent a new class of mammalian 
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non-coding RNAs [20, 21]. They range in size from 100 nt to 9000 nt and they are only 
present in the nuclear fractions. TERRA is evolutionary conserved, because it is found in 
different human cell lines as well as mouse, hamster and zebrafish. Not only the telomeres, 
but also the subtelomeric region is transcribed and TERRA molecules consist of subtelomeric 
derived RNA and telomeric UUAGGG repeats (Figure 2.9). In silico analyses and 
experimental data validated that TERRA transcription starts form different subtelomeres 
towards the chromosome ends. 
 
 
Figure 2.9 Mammalian telomeres comprise (TTAGGG)n DNA sequences, (UUAGGG)n –containing RNA 
molecules (TERRA) and the shelterin protein complex (TRF1, TRF2, POT1, TIN2, TPP1 und Rap1). Many 
additional telomere interacting protein are not shown in this figure. [7] 
 
While the length distribution of TERRA molecules does not vary substantially among 
different mammalian cell lines, the amount of TERRA is variable. There exist many 
evidences that the amount of TERRA correlates with telomere length. This suggests a cell- or 
tissue-specific regulation of TERRA expression.  
Tumour tissue shows often a low level of TERRA molecules compared to healthy tissue, 
leading to the idea TERRA could be down regulated during cancer development in vivo [20] . 
However, up to now, very limiting information about TERRA expression in clinical samples 
is available. 
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TERRA molecules can be recovered exclusively in nuclear fractions, but only 7% of TERRA 
molecules were found in polyA+ nuclear RNA fractions, while 62-64% of transcripts for 
coding genes like c-myc and actin were detected. Most of the TERRA molecules are not poly 
adenylated. Interestingly, almost all polyA+ TERRA molecules are larger than 2kb, indicating 
that short TERRA molecules are abundant and not polyadenylated [21] .   
 
2.3.2 TERRA at telomeres 
 
TERRA molecules form discrete nuclear foci that overlap with telomeric heterochromatin in 
interphase cells as well as inactive metaphase cells. The ability of TERRA molecules to 
interact with telomeres independently of their transcription indicates that TERRA is an 
integral component of telomeric heterochromatin and suggests that TERRA might participate 
in maintaining telomeric architecture. TERRA might be involved in maintaining the 
heterochromatic state of telomeres [7]. 
Because TERRA is detected in only a subset of telomeres, it could be not an essential and 
permanent part of telomeric chromatin, but rather has a transient structural function during 
assembly of telomeres. Alternatively TERRA could have telomeric-state-dependent functions, 
for example, in the establishment of telomeric heterochromatin or in the regulation of 
telomerase.  
TERRA remains associated with telomeres, but it has not been shown whether TERRA 
molecules can move between telomeres or if it remains associated to the telomere, it is 
transcribed from. 
It exist two possible means, by which TERRA could be tethered to telomeres. One is through 
interaction of a telomeric protein with TERRA or, second, by direct interaction of the RNA 
with telomeric DNA. Both options are possible. Up to now, there is no evidence, that 
telomeric proteins are involved in binding of TERRA to telomeres. 
 
2.3.3 Regulation of TERRA 
 
2.3.3.1 Non-sense-mediated decay machinery 
Regulatory pathways exist for both: the abundance and the cellular localization of TERRA.  
For example non-sense-mediated decay (NMD) machinery, which is degrading mRNAs 
containing pre-mature termination codons, has an essential function in displacing TERRA 
from telomeres. Telomere sequences contain termination-codons within the repeat sequence. 
When proteins of NMD machinery were depleted by RNA interference (RNAi), TERRA foci 
on telomeres were strongly increased. This shows a regulating effect of these proteins of 
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TERRA on telomeres. But total levels of TERRA and its half-life were not affected by 
depleting NMD proteins. It is possible, that NMD proteins interact directly with TERRA on 
telomeres.  
There exist two possibilities, by which TERRA abundance could be diminished at telomeres. 
First, NMD proteins could be required for the displacement of TERRA from telomeres, 
without influencing the degradation. Second, they are involved in local TERRA degradation 
at the telomere. [22] 
 
2.3.4.2 RNA interference 
RNA interference (RNAi) is a highly conserved mechanism for gene silencing triggered by 
small interfering RNA molecules (siRNA). These molecules are 22 nucleotides in length and 
double stranded (ds) generated by degradation of long ds RNA molecules by the ribonuclease 
III enzyme Dicer (Fig.2.10).  
  
Figure 2.9 RNA interference 
pathway. Long ds RNA or small 
hairpin RNA (shRNA) is processed 
by Dicer to form a siRNA, which 
associates with RNA-induced 
silencing protein complex (RISC) 
and mediates target sequence 
specifity for subsequent mRNA 
cleavage. [1] 
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It has been shown, that RNAi machinery could be directly involved in heterochromatinization 
of telomeres in yeast. It is possible, that telomere transcription triggers telomere 
heterochromatinization by RNAi, and TERRA serves as precursor RNA to generate telomeric 
siRNA. 
Two lines of evidence exist for RNAi function of TERRA molecules: 
• When mouse cells are transfected with synthetic RNAi, Argonaut1, one of the proteins 
of the RNAi machinery, is increased associated with telomeres and TERRA are 
overproduced [23]. 
• Mouse embryonic stem (ES) cells deficient for Dicer show a low TERRA level when 
compared with wildtype (wt) counterparts [20]. 
 
2.3.4.3 Chromatin state 
As mentioned before, telomeres show some typical features of heteochromatin. Mouse cells 
deficient for histone methyl transferases SUV39H1/SUV39H2 and SUV4-20H1/ SUV4-20H2 
have a decreased level of histone methylation at telomeres and aberrant telomere length. 
Additionally, progressive shortening of telomeres induces a decrease in density of 
trimethylation of histone H3 at lysine 9 and on histone H4 at lysine 20 at telomeres and 
methylation of the subtelomeric region is also decreased. This indicates that the structure of 
mammalian telomeres is regulated epigenetically and this could also be involved in TERRA 
regulation. [7] 
 
2.3.4 Functions of TERRA 
 
2.3.4.1 Telomerase 
As mentioned in 2.3.3.1, TERRA is displaced in human cells at telomeres by NMD factors. 
NMD factors interact directly with telomeric chromatin [21]. One of these factors, 
EST1A/SMG6 was identified due to its sequence-similarity with Est1, a telomerase-
associated protein in S.cerevisiae. Est1 directly binds RNA moiety of telomerase and to ss 
telomeric binding protein Cdc13p, recruiting telomerase to chromosomal ends in S-phase. 
Recruitment and activation of telomerase is till now not well understood in human, and the 
role of EST1A/SMG6 is still uncertain but it might regulate telomerase through TERRA.  
Because TERRA-mimicking oligonucleotides inhibit telomerase activity in vitro and TERRA 
is more abundant when telomeres are long [20, 21], telomerase may be regulated by TERRA 
in a telomere-length dependent manner.  
Consistent with this finding, tumour tissues show a lower level in TERRA expression than in 
corresponding normal tissue. [20] Additionally, tumour-derived and in-vitro-immortalized 
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cell lines show a low level in TERRA expression and presence of telomerase when compared 
with cell lines using the ALT mechanism to maintain telomere length. [24] Overexpression of 
RNaseH in yeast reduces TERRA levels and overcomes the short telomere phenotype, 
indicating that a DNA/RNA hybrid was responsible for this effect [25]. Another line of 
evidence, that TERRA plays a role in inhibiting telomerase is the fact that overexpression of 
TERRA molecules in yeast by using a strong Gal promoter leads to shortening of transcribed 
telomere. [25] 
 
2.3.4.2 Heterochromatin 
Large non-coding RNAs (ncRNAs) can cause changes in epigenetic by recruiting chromatin-
remodelling complexes to genomic loci. For example, X chromosome inactivation in females, 
a large ncRNA, Xist, is involved in inactivating one of two X chromosomes. It would be 
possible, that TERRA functions as a mediator for recruitment of chromatin-remodelling 
enzymes at telomeres to establish or maintain the heterochromatic state. 
Another similarity between X chromosome inactivation and TERRA is the fact, that both are 
regulated by SMG proteins. Female mouse embryonic stem cells fail to undergo X-
inactivation, when they are depleted for SMG proteins. [26] Leading to the suggestion, that 
SMG protein might play a role in chromatin organization involving long ncRNAs. TERRA 
has been shown to colocalize with Xist and specifically with the distal telomere of the 
inactivated X chromosome in female mouse embryos. [27] 
But TERRA localization on the inactive X chromosome does not depend on the expression on 
Xist, indicating that TERRA is not depending on X chromosome inactivation but plays a role 
in telomere specific heterochromatinization. 
 
2.3.4.3 TERRA and development 
It has been shown that TERRA may be regulated developmentally and therefore be important 
for manipulating some features of chromosomal transactions occurring during cellular 
differentiation events. It is interesting to know that TERRA can be found in undifferentiated 
ES cells and can be found associated with both X chromosomes in females and with X and Y 
chromosome in males. After differentiation, only one of the two sex chromosomes is marked 
by TERRA, the inactivated X chromosome in females and the Y chromosome in males, 
showing that TERRA is developmentally regulated. [27] And also when differentiated 
fibroblasts are induced to form pluripotent stem cells with reprogramming factors Oct3/4, 
Sox2, Klf4 and c-myc, TERRA levels are strongly increased [22, 28]. It is not understood if 
the increase in TERRA level is due to reprogramming event, or if reprogramming factors 
function as transcriptional regulators of TERRA. 
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3 Aims of the study 
 
The aims of this study are: 
 
1. Isolation of DNA and RNA from tissue samples of astrocytic brain tumours WHO grade II 
to IV and cell culture cells, and comparison of different isolation methods.  
 
2. A quantitative Real-time PCR assay will be established for the relative measurement of 
telomere DNA length normalized to a reference gene, and the validation of this assay with 
another method, for example terminal restriction fragment (TRF) analysis by Southern blot.  
   
3. The established PCR assay will be validated with ALT positive and ALT negative cell lines 
if it can distinguish the telomere maintenance mechanism. Cells can use telomerase or a 
telomerase independent mechanism termed alternative lengthening of telomeres (ALT) [29], 
resulting defined telomere length characteristics [30]. 
 
4. PCR Assays to detect TERRA will be established. 
 
5. TERRA promoter methylation will be analysed and compared with expression levels. 
 
6. The telomere length and expression will be correlated to clinical parameters (survival of 
patients) and further existing data (telomerase activity, expression levels of telomerase  and 
shelterin genes) 
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4 Methods and Materials 
 
4.1 Tissue samples, clinical data and cell lines 
 
52 tissue samples were derived form 46 patients suffering from astrocytomas and 6 non-
tumour control tissues were acquired from two patients by removal of epileptic foci. The 
samples were frozen on liquid nitrogen after surgical removal and stored at -80°C and liquid 
nitrogen, respectively.  The astrocytomas were histologically graded as WHO grade II 
(diffuse astrocytoma, DA), WHO grade III (anaplastic astrocytoma, AA) and WHO grade IV 
(glioblastoma multiforme, GBM) by Johannes Hainfellner at the Institute of Neuropathology 
(AKH Vienna). 
 
The recruitment phase of the study was for GBMs (grade IV), AA (grade III) and DA (grade 
II) astrocytomas from December 2004 to September 2007 for GBMs, and from September 
2000 to April 2007 for AA and DA. The clinical data from the patients were obtained from 
MD Matthias Preusser and MD Christine Marosi (AKH Vienna) and age of patients were 
calculated (Table 4.1). The local research ethics committee approved the study, and all 
patients provided written informed consent. Patients were followed up until October 01, 2009. 
Patient age at diagnosis, at last follow up and survival were calculated from date of their first 
operation at which grade II to IV disease was confirmed histological.  
 
Patient treatments for low grade astrocytomas were heterogeneous. However, all GBM 
patients were treated with standard therapy. Standard therapy at the AKH Vienna is surgery 
with concomitant chemo- and radiotherapy with akylating agents (1995-2000 CCNU or 
fotemustine/dacarbacine) and since 2000 Temozolamide (personal communication C. 
Marosi). Exept one case all analysed GBMs originated as primary tumours (GBM12 was a 
secondary tumor). 
 
Table 4.1 Number of analysed cases with diagnosis, grading and patient data (gender 
and age at diagnosis) 
WHO grade 
Diagnosis 
 
WHO grade 
Total        ♀           ♂       
n 
Age at diagnosis 
SEM ± SD/year 
DA II 12            8           4                  54 ± 19 
AA III   6            3           3                  45 ± 15 
GBM IV 28          10         18                  46 ± 18 
DA = diffuse astrocytomas, AA= anaplastic astrocytomas, GBM= glioblastomas multiforme 
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14 cell lines were analysed in this study (Table 4.2). 12 of this cell lines are derived from 
astrocytomas, 1 from a desmoplastic cerebellar medulloblastoma (Daoy)) and 1 from a 
primary human osteosarcoma (SAOS-2).  
 
Table 4.2 Cell lines 
Cell line Medium Source 
CCF-STTG1 (CRL-1718) RPMI +10% FCS ATCC 
DBTRG/05MG (CRL-2020) RPMI +10% FCS ATCC 
KG-MH RPMI +10% FCS Established from patient material 
KM-YH RPMI +10% FCS Established from patient material 
LN-140 MME + 10% FCS Dr. Tribolet, Lausanne (Switzerland) 
MGC MME + 10% FCS Dr. Kurata, Tokyo (Japan) 
MR1 MME + 10% FCS Dr. Kurata, Tokyo (Japan) 
T98G (CRL-1690) MME + 10% FCS ATCC 
U-373 MG (HTB17) MNP + 10% FCS ATCC 
YT-BO                                          RPMI +10% FCS Established from patient material 
YU-PM RPMI +10% FCS Established from patient material 
Hs683 (HTB138) DMEM + 10% FCS ATCC 
Daoy (HTB168) * MNP + 10% FCS ATCC 
SAOS-2 (HTB85) ** McCoys + 15% FCS ATCC 
ATCC numbers are given in brackets 
*   originated form desmoplastic cerebellar medulloblastoma 
** originated from primary human osteosarcoma 
MNP      . . .   Minimal essential medium eagle with non essential amino acids and pyruvat 
MEME   . . .   Minimal essential medium eagle 
RPMI     . . .   RPMI-1640 with following additives: adenine, ATP, L-cystine, HEPES 
DMEM  . . .   Dulbecco´s modified Eagles medium 
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4.2 Biochemical methods 
 
4.2.1 Homogenisation of tissues 
Materials:  
• Small glass trough 
• Big glass trough 
• Scalpel 
• Forceps 
• Spattle 
• Ultraturax 
• 3x 500ml cups with about 200ml H2O (for cleaning the Ultraturax) 
 
A big glass trough is filled with ice and a smaller one is placed within the ice. 14ml tubes 
(Falcon) per analyses, spattle, forceps and tubes with snap-frozen tissue samples are placed on 
dry ice. 
Tissue samples are placed on the ice-cooled glass trough with forceps. Semi-frozen tissues are 
quickly cutted with a scalpel. The taken sample (~50 to 100µg) should be representative of 
the whole tumour sample and is transferred quickly with the cooled spattle semi-frozen into 
the cooled 14ml tubes. The rest of the tissue is frozen back on liquid nitrogen for later 
analyses. 
 
Analyses for RNA/DNA Isolation with TRIZOL® Reagent (Invitrogen, USA):  
Place the tissue samples in the 14ml tubes and keep on dry ice. Before addition of 500 µl of 
the Trizol Reagent tubes with the tissue samples are kept shortly at room temperature. Tissue 
samples with Trizol Reagent are homogenized by the power homogenizer Ultra-TURRAX T8 
dispersing tool S8N-5G (IKA, Germany). In detail, 3 pulses of max 5 seconds with power 
level 2 have been applied. The lysat is transferred to 1.5ml tubes with O-ring seal (Eppendorf) 
and stored at -80°C. 
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Analyses for Telomerase Activity (Protein-CHAPS-lysats): 
1x CHAPS Lysis Buffer: 
• 10 mM Tris-Cl (pH 7.5) 
• 1 mM EGTA 
• 1 mM MgCl2 
• 0.1 mM Benzamidine 
• 5 mM β-mercaptoethanol 
• 0.5% CHAPS 
• 10% Glyerol 
 
Prepare 2 ml cryovials (greiner bio-one) for each tissue sample. Chaps lysis buffer is 
supplemented with RNasIn in the following way: 1,300 µl of Chaps lysis buffer and 6.5 µl of 
RNasIn (Promega 40/µl) for 6 analyses. Give 200µl of Chaps + RNasIn to each cryovial and 
put them on ice. Tissue samples are cutted and prepared as described before. Tissue sample is 
given directly into the cryovial with lysis buffer on ice. 
Sample is homogenized by Ultraturax on ice for 1 – 5 seconds (max 2-3 pulses with power 
level 2), remaining pieces are not homogenized to avoid heating of the sample. Incubate the 
homogenates for 30 minutes on ice. Transfer the lysats to a fresh tube and centrifuge 
(1,200g/20minutes/2-8°C). Lysats are than splitted in two aliquots (100µl and 60µl) and 
frozen on dry ice and stored at -80°C. 
From the remaining pellet, a high quality DNA can be isolated [30]. The pellets were stored at 
-80°C. 
Protein extracts can be used for detection of proteins by western blotting. For this purpose, 
protease inhibitor complete (Roche) and phosphatase inhibitor cocktail phosphatase inhibitors 
1mM NaVO4 and 5mM NaF are added to the Chaps lysis buffer to avoid protein degradation. 
 
4.2.2 Isolation of total RNA from Trizol 
 
Materials: 
• Chloroform 
• Isopropanol 
• 75% EtOH 
• RNaseInhibitor 
• RNase free H2O 
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Phase separation: 
100µl of Chloroform (per 500µl Trizol) are added to the lysat, vortexed and incubated at 
room temperature for 2 to 3 minutes. 
Then the sample is centrifuged (12,000g/15minutes/2-8°C). After that three phases are 
visible: the organic phase, the interphase and the RNA-containing aqueous phase. 
 
Precipitation of RNA: 
The aqueous phase is given in a fresh tube (there should be no part of interphase). The 
remaining is left for following DNA and protein isolation and can be stored at -80°C. 
To precipitate RNA, 250µl (per 500µl of Trizol) of isopropanol is added to the aqueous phase 
and mixed by inverting the tube and incubated for 10 to 15 minutes at room temperature. 
After that, the precipitated RNA is centrifuged (12,000g/10min./2-8°C) and supernatant is 
removed. RNA pellet should be visible now. 
 
Washing of RNA: 
The RNA-pellet is washed with at least 500µl of 75% ethanol (per 500µl of Trizol). The 
sample is briefly vortexed than centrifuged (7,500g/5minutes/2-8°C). Supernatant is totally 
removed. 
 
Dissolving of RNA: 
Air-dry the RNA-pellet (15-20 min at RT?), but the pellet should not completely dry, because 
it will not be resolvable very good. To dissolve RNA RNase free H20 with RNasIn (Promega 
40/µl) is prepared (e.g. 200µl of H20 and 2µl of RNasIn). When the pellet is dry, dissolve it in 
30µl of H2O and RNasIn. 
 
4.2.3 Isolation of genomic DNA from Trizol 
 
Materials:      
• 100% Ethanol 
• 0.1M Sodium citrate in 10% Ethanol 
• 75% Ethanol 
• 8mM NaOH 
• 0.1M HEPES 
• 15mM EDTA 
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Genomic DNA is isolated from the TRIZOL-lysat after RNA isolation. After completely 
removing the aqueous phase, the DNA is isolated from the interphase and the organic phase. 
 
Precipitation of DNA: 
DNA is precipitated with 100% ethanol. 0.3 ml of ethanol (per 500µl Trizol) are added and 
mixed by inverting the tube. The sample is incubated at room temperature for 2 to 3 minutes 
and centrifuged (2,000g/5minutes/2-8°C).  
 
DNA washing: 
Supernatant is removed and the DNA pellet is washed two times in a solution of 0.1M sodium 
citrate in 10% ethanol. 500µl (per 500µl Trizol) are added to the pellet. Wash the pellet 30 
minutes at 15 to 30°C by gently shaking (350 rpm) it on a thermomixer. Centrifuge the 
sample (2,000g/5minutes/2-8°c). Supernatant is removed and the washing step is repeated. 
Pellet is dissolved in 0.75 – 1 ml (per 500µl Trizol) of 75% ethanol. Wash it 10 to 20 minutes 
on a thermomixer at 15 to 30°C. Again centrifuge the sample (2,000g/5minutes/2-8°C). 
 
Dissolving of DNA: 
Remove supernatant and let the pellet air-dry. When the pellet is dry (20 min at RT)), it is 
redissolved in 8mM NaOH. Dissolving DNA at low pH is recommended, since DNA can not 
be redissolved in water or Tris-buffer. 
Normally 50µl of 8mM NaOH are used for redissolving DNA. After redissolving the pellet, 
pH is adjusted with HEPES to 7 – 8 and supplemented with 1 mM EDTA as described by the 
manufacturer’s instructions. Once pH is adjusted, DNA was stored at -20°C or 4°C. 
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4.2.4 Isolation of DNA with Maxwell® DNA Purification Kit 
 
 
 
Each cartridge (Fig. 4.1) to be used is placed in the holder and opened. A plunger is placed in 
the last well of each cartridge (well 7). Blue elution tubes are prepared with 300µl of elution 
buffer. 
Fresh or frozen tissue is added to well 1 (containing lysis buffer). 
The Maxwell®16 instrument is switched on and “DNA” is chosen from the menu and then 
press button RUN/STOP. Then choose “Tissue” from the menu and again press RUN/STOP. 
Instrument shows the chosen menu, check if the right parameters for DNA isolation are 
chosen, then press RUN/STOP. Open the door of the instrument and by pressing RUN/STOP 
the platform is extended. Place cartridges and elution tubes within the instrument and press 
RUN/STOP. When the door is closed, the program starts automatically. At the end, tubes are 
removed and stored at -20°C or 4°C. 
 
4.2.5 Determination of DNA concentration 
 
4.2.5.1 NanoDrop ND-1000 Spectrophotometer (Peqlab) 
 
Open the program NC-1000 3.3.0 on the PC. A window is opening, and the instrument is 
demanding for water. Place 1 – 2 µl of water on the instrument and press Ok. 
Remove water from instrument and displace it by 1 – 2 µl of 1xTE buffer and press BLANK. 
Now the samples can be measured. Put 1 – 2 µl of the sample on the instrument and press 
MEASURE. The instrument gives you the amount of DNA but also the purity (260/280).  
This is repeated with every sample to be measured. Results are stored in an Excel file.  
Figure 4.1 Maxwell 16 DNA 
Purification Cartridge. Figure 
shows the contents of a 
cartridge of Maxwell 16 Tissue 
DNA Purification Kit. Figure 
taken from Manual to Maxwell 
16 Tissue DNA purification 
system (Promega). 
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4.2.5.2 Qubit® Fluorometer (Invitrogen, Fisher Scientific) 
 
Materials:  
• Quant-iT™ dsDNA BR reagent 
• Quant-iT™ dsDNA BR buffer 
• Quant-iT™ dsDNA BR standard#1 
• Quant-iT™ dsDNA BR standard#2 
 
All reagents should be brought to room temperature before using them. Prepare one tube for 
every sample to be measured on Qubit fluorometer and for each standard. For Quant-iT 
working solution, the dsDNA BR (broad range) reagent is diluted 1:200 with the Quant-iT 
dsDNA BR buffer. 200 µl of this working solution are needed for every standard and every 
sample to be measured (Table 4.3). 
 
Table 4.3 DNA quantification on Qubit fluorometer 
 
 
For standards: 190 µl of working solution and 10 µl of standard 1 and standard 2, respectively 
are mixed in an 250 µl tube and are briefly vortexed and spinned down.  
 
For samples: 199 µl of working solution and 1µl of the DNA to be measured are mixed in and 
250 µl tube and also briefly vortexed and spinned down. (If necessary, bigger amounts of 
DNA can be used for measurement. And in the opposite, if DNA is too concentrated, an 
appropriate dilution of DNA is used for quantification).  
 
All samples and standards are incubated for 2 minutes at room temperature. Qubit Data 
Logger is opened on the PC and the tubes are placed in the fluorometer. First the instrument is 
calibrated with standard 1 and standard 2.  
 
 
 Standards 
µl 
Samples 
µl 
Volume of Working solution 190 199 
Volume of Standard 10 0 
Volume of Sample 0 1 
Total volume in each assay tube 200 200 
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Then sample DNAs are quantified by placing them in the instrument. The results of 
measurement are saved as Excel file and the formula to calculate the amount of DNA is:                                                                    
 
Concentration of DNA = QF value × (200)/µl of sample 
 
4.2.5.3 Determination of RNA concentration 
 
Samples are stored at -80°C and are heated for 10 minutes to 55-60°C after every thawing to 
redissolve RNA and to avoid RNA aggregates. 
RNA concentration can be measured with NanoDrop ND-1000 Spectrophotometer or Qubit 
Flourometer (see also 4.2.5 Determination of DNA concentration). 
For determination of RNA concentration with Qubit fluorometer the Quant-iT™ RNA BR Kit 
is used.  
 
4.2.6 Synthesis of complementary DNA (cDNA) 
cDNA- synthesis was done in 20 µl by the manufacturer’s protocol for RevertAid First Strand 
cDNA synthesis kit (Fermentas, Germany). Therefore, RNA sample is thawed, centrifuged 
and placed on ice. 1µg of RNA were given in a 0.5 ml PCR tube and filled up to a volume of 
max. 11.5 µl with ddH2O. A random hexamer primer (5´-N6-3´) was added to the RNA (1µl 
of primer; 0.2 µg/µl) and incubated for 5 minutes at 70°C. Afterwards the tube was 
immediately put on ice. 4µl of a 5x reaction buffer was added and heated for 5 minutes at 
25°C. Finally, 1µl of RevertAid M-MuLV reverse transcriptase was added and the total 
reaction mixture was incubated for 10 minutes at 25°C, 60 min at 42°C, 10 min at 70°C. The 
reaction was then stopped on ice. The cDNA sample was diluted 1:25 to a final volume of 
500µl by adding 480µl of ddH20. This would allow 50 PCR experiments with a 20 µl scale. 
Mastermix (for each sample):  
• 1µl Random hexamer primer (0.2µg/µl) 
• 4µl 5x Reaction Buffer 
• 0.5µl Ribonuclease Inhibitor (20u/µl) 
• 2µl dNTP Mix (10mM) 
• 1µl M-MuLV Reverse Transcriptase (200 U/µl) 
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4.3 Polymerase chain reaction (PCR) 
PCR is used to amplify short, well defined regions of a DNA. Two oligonucleotide primers, 
target DNA and DNA polymerase are necessary for the amplification. DNA polymerase 
catalyzes the replication of the DNA in adding nucleotides to the 3´OH-end of the primer and 
synthesizing complementary DNA sequences. Oligonucleotide primers have usually a length 
of 15 – 30 bases, which can vary greatly. The PCR method can be used to amplify specific 
peaces of a DNA strand, generally 100bp to 3 kb in length.  
4.3.1 Steps in PCR  
PCR consists of different phases:  
1. Denaturation: 
In this phase, the DNA double strand is separated into the two single strands at a high 
temperature (95°C). Primers are now able to bind to the single strands. 
2. Annealing 
This step is needed for the annealing of primers to the now single stranded DNA. The 
temperature here is primer-specific. 
Exactly one should say, the primers bind anywhere and detach very quickly. But if a primer 
binds to the correct position, this binding is stable. For annealing, primers have to be in molar 
excess over DNA, otherwise separated strands of DNA would anneal. 
3. Extension 
In this phase, polymerase produces the counterpart of the template DNA. This step is carried 
out at a temperature of 72°C. The following cycle starts again with denaturation. The primers 
bind in the following annealing phase to the template DNA and to the products of previous 
cycles.  
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4.3.2 Primer design and PCR components 
4.3.2.1 Primer design  
Primers are oligonucleotides and are ordered from VBC Genomics (Vienna). The primer 
sequences are part of the sense and anti-sense strand of the double stranded DNA to be 
amplified. So, the primer sequences are specific for each amplified dsDNA and are already be 
known. The primer sequences in Table 4.4 were taken from literature or designed with the 
Clone Manager9 program (Scientific & Educational Software, NC, USA). Information on 
DNA and RNA sequences for genes and subtelomeric regions were obtained from reference 
sequences, NC and NM accessions, respectively, from public databases at the National Center 
of Biotechnology Information (NCBI; http.//www.ncbi.nlm.nih.gov). Sequence data were 
imported into the Clone Manager9 program. 
Primer sequences for two housekeeping genes 36B4 and β-globin were from literature [31]. 
36B4 codes for the acidic ribosomal phosphoprotein P0 and β-globin bilds together with α-
globin the most commonly form of haemoglobin.  
Primers for amplifying repetitive telomeric repeats have to be specially designed and were 
taken from literature [32]: 
 
• They are designed in a way, that the polymerase can start at the 3´-end, but only if 
primers are bound to telomeric sequence, and not, if two primers bind. If two primers 
bind, four base pairs and every fifth and sixth base pair give a mismatch. And so, the 
base on the 3´-end stays unpaired and polymerase can not start elongation, if two 
primers pair. 
• Primers should bind at the end of previous produced amplicons and not somewhere in 
the center. So these primers have six bases on their 5´-end, which do not pair, when 
the rest of the primer is annealed to telomeric sequence.  The counterpart for this six 
bases is build on the 3´-end of each produced amplicon and should inhibit binding of 
primers somewhere in the center of a amplicon. 
 
• The GC-content should be more than 50% and all bases should be distributed equally 
and melting temperature of the two primers should not differ more than 1°C. 
 
All primers used were analysed for proper function with the CloneManager program (Table 
4.5).  
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Table 4.4 Primersequences 
a) Telomere length assay 
Primer Length  
Tel1b 5´-CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GGT-3´ 
Tel2b 5´-GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT-3´ 
  
hbg3 5´-TGT GCT GGC CCA TCA CTT TG-3´ 
hbg4 5´-ACC AGC CAC CAC TTT CTG ATA GG-3´ 
    
36B4u 5´-CAG CAA GTG GGA AGG TGT AAT CC-3´ 
36B4d 5´-CCC ATT CTA TCA TCA ACG GGT ACA A-3´ 
Primers tel1b und tel2b were described in [32]   
Primers 36B4u und 36B4d were described in [31] 
Primers hbg3 und hbg4 were described in [33] 
 
b) 2p and 18p TERRA expression 
Primer Sequence 
chr2_590 5´-TAA GCC GAA GCC TAA CTC GTG TC-3´ 
chr2_738 5´-GTA AAG GCG AAG CAG CAT TCT CC-3´   
  
chr18_617 5´- CCT AAC CCT CAC CCT TCT AAC-3´ 
chr18_725 5´-ACC AGC CAC CAC TTT CTG ATA GG-3´ 
    
2253BACT_for 5´-GGA TGC AGA AGG AGA TCA CTG-3´  
2253BACT_rev 5´-CGA TCC ACA CGG AGT ACT TG-3´ 
Primers were designed with Clone Manager9 program (Scientific & Educational Software, NC, USA) to amplify 
the subtelomeric region of short arms of chromosome 2 and 18, respectively. 
 
c) Methylation specific PCR 
Primer  Sequence 
MP_HC2 FWD 5´- GTA TTG TAG GTG TAT AGT TGT ATA AG -3´ 
MP_HC2 REV 5´- TAA AAT TCC ACC TAT CTC TAT AC -3´ 
MP_HC2_REV_S 5´- TAA TAC GAC TCA CTA TAG GGG ATC GAT CTA AAA TTC CAC CTA TCT CTA TAC -3´ 
  
MP_HC18 FWD 5´- GTA AGG TTT GTG TTG ATT AGG A -3´ 
MP_HC18 REV 5´- AAA ATA AAA CTA TAT TCT CAT CAA C -3´ 
MP_HC18_REV_S 5´- TAA TAC GAC TCA CTA TAG GGG GCC GAT CCA AAA TAA AAC TAT ATT CTC ATC AAC -3´ 
Primers MP_HC2 FWD, MP_HC2 REV, MP_HC18 FWD and MP_HC18 REV are described in [24] 
Primers MP_HC2_REV_S and MP_HC18_REV_S are modified (extended at the 5’ end by T7 primer 
sequences) 
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Table 4.5 Primer properties 
 
a) Telomere length assay 
Primer 
 
Length  
(nt) 
N-content 
A-G-C-T 
GC-content 
(%) 
Tm 
(°C) 
Tel1b 39 0-18-1-20 48.7% 78.4°C 
Tel2b 39 5-3-18-13 53.8% 72,3°C 
     
hbg3 20 2-5-6-7 55% 56,7°C 
hbg4 23 6-4-8-5 52.5% 56,1°C 
     
36B4u 23 7-8-4-4 52.2% 56,5°C 
36B4d 23 8-3-8-6 44% 57,9°C 
 
 
b) 2p and 18p TERRA expression 
Primer 
 
Length  
(nt) 
N-content 
A-G-C-T 
GC-content 
(%) 
Tm 
(°C) 
chr2_590  23 6-7-5-5 52% 66°C 
chr2_738 23 7-6-6-4 52% 66°C 
     
chr18_617 21 5-11-0-5 52% 61°C 
chr18_725 23 7-6-6-4 52% 66°C 
 
 
c) Methylation specific PCR 
Primer 
 
Length  
(nt) 
N-content 
A-G-C-T 
GC-content 
(%) 
Tm 
(°C) 
MP_HC2 FWD 26 7-0-8-11 30 56 
MP_HC2 REV 23 8-7-0-8 30 54 
MP_HC2_REV_S 51 17-13-6-15 37 71 
     
MP_HC18 FWD 22 5-0-8-9 36 58 
MP_HC18 REV 25 13-5-0-7 20 53 
MP_HC18_REV_S 54 21-13-7-13 37 73 
Information about primer properties are taken from CloneManager 9 program, primer details and from VBC 
genomics synthesis reports. 
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Dissolving of delivered primers: 
 
• Briefly spin down lyophilized primers 
• Dissolve primer in given volume of 1xTE (synthesis report) for 100pmol/µl 
• Vortex and briefly spin down 
• Dissolve primers 10 minutes at 37°C  
• Again, vortex and briefly spin down 
• Put primers on ice 
• Prepare a 1:50 working solution of primers in 0.1x TE (e.g. 10µl of forward primer, 
10µl of reverse primer and 480µl of 0.1x TE) 
 
4.3.2.2 PCR components 
PCR components for all primers used were the same (tel1b+tel2b, 36B4d+36B4u, 
hbg3+hbg4, chr2_590+chr2_738, chr18_617+chr18_725) 
 
10 µl 2 x PCR Master Mix (Promega, Promega, M7502) 
1 µl Primer forward and reverse (2pmol/µl) 
8 µl (20ng) template DNA 
20 µl total volume  
 
4.3.2.3 PCR protocol 
A PCR was performed for amplification of telomeric repeats with primers tel1b and tel2b, for 
the single copy genes 36B4 and ß-globin with primers 36B4u and 36B4d and primers hbg3 
and hbg4. For specific amplification of TERRA from chromosomal end 2p and 18p primers 
chr2_590 and chr2_738 and primers chr18_617 and chr18_725 were used on a thermocycler 
HYBAID Omn-E (GenXpress) under the following PCR conditions (Table 4.6). 
 
Table 4.6 PCR conditions 
PCR phase Temperature 
°C 
Time Number of cycles 
Initial denaturation 95 2 minutes 1 
Denaturation 95 15 seconds 28 
Annealing/extendsion 60 1 minute 28 
Final extension 60 5 minutes 1 
Cycling conditions are the same for primers tel1b + tel2b, 36B4d + 36B4u and hbg3 + hbg4 
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4.4 Polyacrylamidegelelectrophoresis (PAGE) 
Materials:  
Gels    
• 12.6 ml ddH2O 
• 375 µl 40 x TAE 
• 1.95 ml Acrylamide/Bis 19:1 Solution (Biorad)  
for polymerisation start add and mix: 
• 20.8µl 25% APS (Ammoniumperoxodisulfate, MERCK, Germany) 
• 20.8µl TEMED (N,N,N´,N´-Tetramethylethylenediamine, Sigma, USA) 
poor in prepared trays for gels (BioRad PAGE System3) 
 
40 x TAE 
• 96.8 g Tris base 
• 22.8 ml glacial acetic acid 
• 40ml EDTA (pH 8; 0.5 M) and fill to 1000 ml with ddH2O and autoclave 
 
4.4.1 Preparing the samples: 
3µl aliquots of PCR products are added to 1.5ml or 0.5ml tubes (Eppendorf) containing each 
7µl ddH2O and 2 µl of 6 x loading dye. 2µl of a 50bp molecular weight marker (Fermentas, 
#SM0373) are mixed in a tube with 8µl of ddH2O and 2 µl of 6x loading dye.   
 
4.4.2 Running the gel: 
Gel electrophoresis was performed at constant 80V for 90 minutes or until the dye reaches the 
end of the gel with a power supply (Power Pac 3.000, Biorad, USA). 
 
4.4.3 Visualisation of DNA: 
DNA bands in the gel are stained with a 1:10,000 dilution of Vistra Green (Amersham Life 
Science) and visualised in a Fluorimager 595 (Molecular Dynamics) using the filter 530DF30. 
Alternatively, gels are stained by EtBr (1:10.000) and visualised with Fluorimager 595 or 
GelDoc System (BioRad). 
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4.5 Cloning of PCR products 
 
For direct insertion of Taq polymerase-amplified PCR products in a plasmid vector, TOPO 
TA Cloning Kit (Invitrogen) was used and the cloning was performed according to 
manufacturer’s protocol. Taq polymerase adds a single 3´-A nucleotide overhang to each end 
of the PCR products. The PCR products were 75bp for 36B4 and 73bp for hbg. The cloning 
vector was pCRII-TOPO and contains covalently bound topoisomeraseI, which enabled 
within minutes direct ligation of the PCR products into the vector.   
 
4.5.1 Preparing competent E.coli cells (Simple and efficient methode - SEM protocol) 
Materials: 
•   TB-Buffer:   10mM Pipes 
                                   15mM CaCl2 
                                   250mM KCl 
Adjust the pH to 6.7 with KOH and autoclave 
 
• MnCl2-Buffer:   0.544g MnCl2 (550 mM) 
                                 5ml ddH2O 
 
E.coli TOP10 cells were obtained from strike out plates from old competent cells or from the 
frozen bacterial LB-stock collection at -80°C. 50µl of over-night culture of E.coli cells are 
inoculated into 200 ml of LB medium and incubated at room temperature overnight with 
shaking at 250 rpm. When cell suspension reaches an OD600 of ~0.6, the cells are immediately 
put on ice, and are splitted into 50 ml tubes (Falcons) and incubated for 10 minutes on ice. 
Solution is centrifuged at 4°C/2,500g for 10 minutes and the supernatant (should be clear, if 
not, centrifuge for another 10 minutes) is discarded. In the meanwhile, 4 ml of 550 mM 
MnCl2 solution is added to 36ml of TB buffer. Pellet is resuspended in 40 ml of ice-cold TB 
buffer (+ MnCl2) and incubated for 10 minutes on ice. Cell suspension is then again 
centrifuged at 4°C/2,500g for 10 minutes and the supernatant is discarded.  
Pellet is resuspended in 10 µl of ice-cold TB buffer and DMSO is added to an end 
concentration of 7 percent of volume (700µl/10 ml) and incubated for 10 minutes on ice. 
Finally, the competent cells are aliquoted in 500µl in 1.5ml tubes (Eppendorf), snap-frozen on 
liquid nitrogen and stored at -80°C. 
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4.5.2 Cloning reaction 
Salt Solution (TOPO TA Cloning Kit, Invitrogen, #K4600-01) 
• 1.2M NaCl 
• 0.06M MgCl2  
 
pCRII-TOPO (TOPO TA Cloning Kit, Invitrogen) 
• 10ng/µl plasmid DNA in: 
• 50% glycerol 
• 50mM Tris-HCl, pH=7.4 
• 1mM EDTA 
• 1mM DTT 
• 0.1% Triton X-100 
• 100µg/ml BSA 
• Phenol red 
 
Figure 4.2 pCRII-TOPO map Map shows features of the vector and the sequence surrounding the cloning site. 
Arrows indicate transcription start sites for Sp6 and T7 polymerase. Figure from TOPO TA Cloning Manual, 
Invitrogen. 
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The reaction mixture is set-up in a 1.5 ml tube (Eppendorf): 
• 2µl of PCR-product (e.g. 36B4 or hbg amplicons) 
• 0.5 µl of cloning vector (pCRII-TOPO) 
• 0.5 µl of salt solution 
• 3µl total volume 
 
Reaction mixture was mixed gently and incubated for 20 minutes at room temperature. After 
incubation the tube was placed on ice.  
 
4.5.3 SEM Transformation of E.coli cells  
Materials 
SOB-Medium (for 1 litre):  
• 20g Trypton 
• 5g Yeast extract 
• 0.5g NaCl 
• 10ml 250mM  KCl ( (1.86g NaCl/100ml H2O)   
• pH is adjusted to 7 and autoclaved  
 
SOC-Medium:  
• 6ml SOB-Medium 
• 60µl (1/100 Vol) 1M MgCl2 solution (9.5g MgCl2/100ml) 
• 60µl (1/100 Vol) 2M glucose solution (36g/100ml) 
 
LB-Medium:  
• 8g LB  
• filled to 400 ml with ddH2O 
• autoclaved and when cooled down,  
• optional: 400µl of ampicillin (1:1000) stock solution (100mg/ml) are added 
 
LB-Medium für Platten:  
• 8g LB 
• 6g Agar 
• fill to 400 ml ddH2O and autoclave 
• optional for Amp100+ plates, 400µl of ampicillin stock solution are added (to an end 
concentration of 100µg/ml) 
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SEM (simple and efficient method) chemical transformation was performed to transfer the 
vector construct into competent E.coli. Competent cells were thawed on ice. The TOPO TA 
Cloning Kit allows a blue/white screening without IPTG in E.coli TOP10 cells. 1µl of the 
cloning reaction mixture or 1µl of 10pg/µl pUC vector (for transformation control) are placed 
in a tube on ice. 200µl of bacteria solution is added and these mixtures are incubated for 20 
minutes on ice.  
 
After incubation E.coli cells are heat shocked for 30 seconds at 42°C in water bath. 800? µl of 
pre-warmed SOC medium are immediately added and the whole mixture is transferred to a 14 
ml tube (Falcon). Cells are incubated at 37°C for one hour, by shaking at 230 rpm. In the 
meantime, 40µl of of an X-Gal stock solution (100 nmol/µl) are spreaded on the ampicillin 
containing plates. After one hour, the bacteria solutions are transferred to 1.5 ml tubes. The 
tubes are centrifuged for 3 minutes at 6,000 rpm at room temperature. Supernatant is removed 
to a small rest of 50-150 µl and the cell pellet is resuspended in this small rest of supernatant. 
The resuspensions are spread on LB plates with ampicillin and X-Gal and incubated over-
night at 37°C. 
 
Next day, white colonies are transferred with a sterile tooth pick to a 14 ml tube (Falcon) 
containing 5 ml of LB medium with ampicillin and incubated over night at 37°C to obtain 
cultures of individual clones for further analyses. 
 
4.5.4 Transformation rate 
 
To calculate the transformation rate it is essential to know the amount of pUC19, used in the 
transformation control reaction. 1µl of pUC19 are used in the control reaction, and 1 µl 
correspond to 10 pg of plasmid DNA. This is important to know to calculate the 
transformation rate in number of colonies per µg plasmid DNA transformed. 
 
1µl of pUC19  …  10pg 
10 pg  . . . x colonies 
1 µg   . . .  x * 105 colonies 
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4.6 Isolation of plasmid DNA 
 
4.6.1 WIZARD Plus SV Miniprep DNA Purification System 
 
Plasmids were isolated from the E.coli cells with the WIZARD Plus SV Miniprep DNA 
purification system (Promega) with manufacturers’ instructions.   
 
Material: 
• Cell Resuspension Solution 
• Cell lysis Solution 
• Neutralization Solution 
• Alkaline Protease 
• Column Wash Solution 
• Spin columns 
• Collection tubes 
 
4.6.1.1 Harvesting of E.coli cells 
1.5 ml of bacteria culture is centrifuged in 1.5ml tubes (Eppendorf) for 2 minutes at 10,000 g 
and the supernatant is discarded. The centrifugation step was repeated (2-3x) to increase the 
amount of bacteria up to 4.5ml culture volume. 
 
4.6.1.2 Lysis and precipitation 
The cell pellet is resuspended in 250 µl of resuspension solution and 250 µl of cell lysis 
solution are added, vortexed and incubated for 3 minutes. After incubation 10µl alkaline 
protease solution are added, vortexed and incubated for 5 minutes. After 5 minutes, 350 µl of 
neutralization solution are added and centrifuged for 10 minutes at 14,000 g. 
 
4.6.1.3 Purification and Elution 
The supernatant is transferred after centrifugation to  a spin column and centrifuged for 1 
minute at 14,000 g, flow-through is discarded and 750 µl of column wash solution is added 
and again centrifuged for 1 minute at 14,000 g and the flow-through is discarded, again 
centrifuged for 1 minute and flow-through is discarded. Now the spin column is centrifuged 
for 2 minutes at 14,000 g. 50 µl of nuclease-free water or 1xTE (keeps DNA more stable after 
multiple freeze/thaw cycles) are placed on the membrane of the spin column and incubated 
for 2 minutes. To elute the plasmid DNA, spin column is centrifuged for 1 minute at 14,000g. 
Finally, the spin column is discarded and plasmid DNA is mixed and stored at -20°C.  
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4.6.2 STET Boiling Plasmid Miniprep (from Stratagene) 
 
Materials:    
STET-buffer:    
• 8% Saccharose 
• 0.5% Triton X-100 
• 50mM Tris pH8 
• 50mM EDTA 
Fill to 1l with ddH2O and autoclave, stored at +4°C 
 
Lysozyme:  50mg/ml stock in STET buffer, stored at -20°C 
 
RNase A: 100mg/ml stock (in 10mM Tris-HCl pH7.5 and 15mM NaCl heat to 100°C   
                      and cool it to room temperature, stored at -20°C 
 
Isopropanol 
EtOH 75% (e.g. 7.5ml EtOH and 2.5 ml Water) 
 
Fill cell suspension in 1.5ml tubes (Eppendorf) and centrifuge for 3 minutes at 10,000 g and 
discard supernatant. The centrifugation step can be repeated (2-3x) to increase the amount of 
bacteria and the yield of plasmid DNA. For each experiment 100µl STET buffer and 10µl 
Lysozyme stock are mixed in a 1.5ml tube. 110µl of this STETL buffer are added to each 
bacteria pellet and resuspended by multiple pipetting.  
 
Suspensions are heated to 95°C for 1 minute. After heating, the suspensions are centrifuged 
for 10 minutes at 4°C/10,000 g. Pellet is carefully discarded with a toothpeak prior to that 
soaked with RNaseA solution. Then 110µl of isopropanol are added to the supernatant, mixed 
and centrifuged for 15 minutes at 4°C/10,000 g. Supernatant is discarded and the pellet is 
dried for 15 min at RT. The dried pellet is resuspended in 50µl 1xTE. 
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4.6.3 Alkaline Lysis Miniprep 
 
Materials: 
Solution I:  
• 15 mM Tris-HCl, pH8, 10mM EDTA, 100µg/ml RNase A; filter-strerilize   
            and store at +4°C 
Solution II:  
• 0.2N NaOH, 1% SDS; filter-sterilize 
Kalium-Acetat, pH5.5 autoclaved and stored at 4°C 
Isopropanol 
75% Ethanol 
 
Cell suspension is centrifuged in 1.5ml tubes (Eppendorf) for 1 minute at 14,000g, the 
supernatant is discarded and the pellet is resuspended in 0.3 ml solution I. 0.3 ml solution II 
are added and the mixture is incubated for 5 minutes at room temperature (RT). After the 
incubation, 0.3 ml Kalium-Acetat is added slowly and the reaction mix is placed on ice for 5 
to 10 minutes, and centrifuged for 10 minutes at 14,000 g. Supernatant is transferred to a new 
1.5ml tube with 800µl of isopropanol. Tube is inverted a few times and incubated on ice for 5 
to 10 minutes. The suspension is centrifuged for 15 minutes at 14,000 g at RT. Supernatant is 
discarded and the pellet is washed with 0.5 ml of 75% EtOH. The washed pellet is centrifuged 
for 5 minutes at RT and 14,000g. Supernatant is discarded and the pellet dried for 5 to 10 
minutes. The dry pellet is resuspended in 40µl of 1xTE and stored at -20°C. 
 
4.7 Real-time PCR 
The Real time PCR system is based on the detection and quantification of a fluorescent 
reporter. By recording the amount of fluorescence emission at each cycle, the PCR reaction 
can be monitored during the exponential phase. At this phase the first significant increase in 
the amount of the amplicon correlates to the initial amount of target template. The higher the 
starting copy number of the nucleic acid target, the sooner a significant increase in 
fluorescence is observed.  
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4.7.1 Method of quantification  
One method of quantification is a double-stranded (ds) DNA binding dye chemistry, which 
quantitates the amount of PCR products (including non-specific amplification products such 
as primer-dimers) by using a non-sequence specific fluorescent intercalating agent like SYBR 
Green. SYBR Green binds to the minor groove of dsDNA, but does not bind to single-
stranded (ss) DNA (e.g. primers). It shows very little fluorescence as long as it is in solution 
but shows strong fluorescence after binding to dsDNA, leading to the generation of an 
excitation-emission profile, which allows the general detection of amplicon accumulation 
during PCR. At the end of the PCR the products can be heated (e.g. from 60 to 95 °C) and 
melting curves are generated. Each product does have a characteristic melting temperature. 
The melting curves can be used to differentiate between specific and non-specific amplicons 
based on the observed melting temperature (Tm) of the reaction end-products. Additionally, 
PCR products can be analysed by PAGE. 
4.7.2 Real time qPCR assay for relative telomere length 
 
4.7.2.1 PCR components 
 
PCR components for the determination of telomere length measured on 7000 Real-time PCR 
system (Applied Biosystems): 
• 9 µl of template DNA (20 ng) 
• 1 µl of forward and reverse primer Tel1b and Tel2b (2pmol/µl each) 
• 10 µl of  Power SYBR Green Master Mix (ABI) 
20 µl total volume 
 
PCR components for the quantification of expression of telomeres (overall TERRA) on 7500 
Fast Real-Time PCR system (Applied Biosystems): 
• 4 µl of cDNA 
• 0.16 µl of forward and reverse primers Tel1b and Tel2b (10pmol/µl each) 
• 3.84 µl of Fast SYBR Green Master Mix (ABI)  
8 µl total volume 
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PCR components for the quantification of expression of specific TERRA (2p and 18p 
TERRA) on 7500 Fast Real-Time PCR system (Applied Biosystems): 
• 4 µl of cDNA 
• 0,16 µl of forward and reverse primers (10pmol/µl each) 
• 3.84 µl of Maxima SYBR Green qPCR Master Mix (Fermentas)  
8 µl total volume 
 
 
4.7.2.2 PCR protocol 
 
The genomic DNA isolated from Trizol (chapter 4.2.3) serves as template for the quantitative 
real-time PCR assay to measure relative telomere length as T/S ratio. As endogenous control 
the single (S) copy gene 36B4 PCR assay was used to normalize the telomere (T) PCR assay. 
 
 
Relative telomere length was calculated by division of the values obtained for telomeres (T) 
by the values obtained for 36B4 (S). Real time PCR was performed on ABI PRISM7000 
Sequence Detection System (Applied Biosystems).  
Reactions were measured in triplicates with each 100nM telomere-specific (T) primers Tel1b  
and Tel2b or in duplicates with each 100nM single copy 36B4 gene (S) primers 36B4u and 
36B4d. DNA samples, primers and PCR Master Mix (Power SYBR Green PCR Master Mix, 
ABI) were thawed, mixed, down-spinned and placed on ice.  
 
Three thermal cycling parameters were tested for both T and S assay (telomeric repeats and 
single copy gene 36B4). 
 
Figure 4.3: Location of gene 
36B4 on chromosome 12 
Position of 36B4 
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60°C:      Initial denaturation:                            95°C   10 minutes          1 cycle 
                Denaturation:                                      95°C   15 seconds 
                Annealing and Extension                   60°C     1 minute          40 cycles 
as described in [32] for both assays. 
 
58°C:     Initial denaturation:                             95°C   10 minutes           1 cycle 
               Denaturation:                                      95°C   15 seconds             
               Annealing and Extension                    58°C    1 minute           40 cycles 
as described in [31] for amplification of gene 36B4. 
 
54°C:     Initial denaturation                               95°C    10 minutes          1 cycle 
               Denaturation:                                       95°C    12 seconds 
               Annealing and Extension                    54°C     2 minutes        40 cycles 
as described in [31] for amplification of telomeric repeats. 
 
Ct values of technical replicates with a standard deviation of Ct >0.5 were excluded from the 
analysis. Relative quantities (RQ) of  T/S gene levels were calculated according to the Pfaffl 
method [34]. The efficiency (E) of Tel and 36B4 PCR was 0.81 and 0.97, respectively, as 
determined by standard curves of a DNA probe 1:1 dilution series with 5 dilutions.  
Real-time PCR quantitates the initial amount of template and is an alternative to other forms 
of quantitative PCRs that detect the amount of final amplified product at the endpoint. Real 
time PCR monitors the fluorescence emitted during the reaction as an indicator of amplicon 
production during each cycle of the PCR in opposite to the endpoint detection. 
4.7.2.3 Relative Quantification 
Relative quantification calculates the difference in the amount of gene of interest in a sample 
compared to a reference sample ∆Ct is Ct (sample) – Ct (reference sample) for all genes 
including the reference gene. In the next step the difference between ∆Ct for gene of interest 
and ∆Ct for housekeeping gene is calculated (∆∆Ct). Results are expressed as the ratio of 
amount of gene (expression of gene) in sample of interest versus reference sample and are 
termed fold change (FC) or relative quantity (RQ). FC or RQ = 2-∆∆Ct. For example, the 
relative amount or expression level of a gene is 3 times higher in the sample of interest 
compared to the reference sample and compared to the housekeeping gene.  
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a) Pfaffl Model (Pfaffl, 2001)[34] 
RQ = (Etarget + 1)
 ∆Ct target (control-sample) / (Eref +1)
 ∆Ct reference (control-sample) 
 
In this equation, the denominator contains the house keeping gene and the numerator contains 
the target gene (gene of interest). The formula is corrected for the efficiency (E) of the 
amplification of the target as well as the house keeping gene. If the efficiency of an assay is 
100%, the amount of amplicon doubles with every cycle.  
 
After determination of efficiency of an assay, efficiency + 1 give the increase in amplicon per 
cycle. What means, when the Ct values of reference and sample are 3 cycles apart, they differ 
23 = 8fold in the amount of amplicon. If the efficiency is for example 90%, there is a 1.9 fold 
increase per cycle.  
 
b) ∆∆Ct method (Livak and Schmittgen, 2001)[35] 
 
RQ = 2
–(∆Ct sample – ∆Ct control)
 = 2
-∆∆Ct 
 
This method is a shortened version of the “Pfaffl” method. Two presumptions are made for 
this equation: 
 
1. Efficiency of amplification of target and house keeping gene is close to 100%.  
 
2. The difference in expression of the house keeping gene between reference sample and 
sample of interest in all measured probes is 0. Practically this values should not vary 
more than 10% 
 
We used the Pfaffl method with measured Efficiencies of the Real time PCR assays in this 
study. 
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4.7.2.4 Determination of the Efficiency of a PCR assay 
 
A standard curve is created to determine the efficiency of a PCR assay. Therefore, 1:1 
dilution series are used. The Ct-values of each step in the series should be exactly one cycle 
apart, if the amplification works with an efficiency of 100%. The plot of Ct versus log of 
initial template concentration should have a gradient close to -3.33. The gradient is negative, 
because the Ct-value gets smaller with higher template concentration, and should lie between 
-3.1 and 3.6. 
In this study, standard curves were created for telomere repeats (T) and housekeeping gene 
36B4 (S) assays. Plasmid pSP73 was used as a template for the standard curve of the T assay, 
contains an 800 bp fragment of cloned telomere with ~120 telomeric repeats (Fig.4.3). 
Plasmid pSP73 was kindly provided by Dr. Kiyozuka Y [36] under allowance of Dr. Titia De 
Lange [37]. Plasmid pCRII TOPO with a cloned PCR fragment of gene 36B4 was used for 
the standard curve and determination of efficiency for gene 36B4(S) assay. 
DNA used for these standard curves had an initial concentration of 20 ng (20 ng, 10 ng, 5 ng, 
2.5 ng, 1.25 ng). Each step was run as a triplicate. 
 
Figure 4.4 Vector map for pSP73. The telomere-repeat fragment is cloned within the multi-cloning site between 
SP6 and T7 primer sites. Insert is cloned into EcoRI cutting sequence. 
 
 
 
800bp TTAGGG 
repeats inserted 
in EcoRI  
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4.7.2.5 TERRA expression 
 
Overall telomere expression analyses were performed with a two step RT-PCR procedure. 
First, 1µg total RNA was reverse transcribed with random hexanucleotide primers and 
RevertAid First Strand cDNA Synthesis Kit (Fermentas), according to manufacturer’s 
protocol. Second, real time PCR was performed on ABI PRISM 7500Fast Sequence Detection 
System. 
For overall TERRA, FAST SYBR Green Master Mix (Applied Biosystems) and Fast program 
was used (7500 Fast System Software, version 1.4, Applied Biosystems). 40ng total RNA 
aliquots were analysed with 200nM primer concentration each under conditions as described 
in Table 4.7 for relative telomere length measurement (Chapter 4.7.2). Relative quantities 
(RQ) of overall TERRA were calculated as described before. 
 
Table 4.7 PCR conditions for overall TERRA measurement 
PCR phase 
 
Temperature 
°C 
Time Number of 
cycles 
Initial denaturation 95 20 seconds 1 
Denaturation 95 3 seconds 40 
Annealing/extendsion 60 30 seconds 40 
Melting curve 95 
60 
15 seconds 
1minute 
2 
2 
 
 
Real time PCR gene expression assays for TERRA quantification specific for chromosome 2p 
and chromosome 18p were established (Table 4.8). Reactions were performed in triplicates 
with 200 nM chromosome specific primers from the subtelomeric region chr2_F and chr2_R; 
or for 18p-TERRA with 200 nM chr18_F and 200 nM chr18_R. Primers are described in table 
4.4 and table 4.5. As house keeping gene, again 36B4 was used.  
Additionally for the 2p- and 18p-TERRA assays, a second house keeping gene, beta actin, 
was used to normalize. Beta actin is used often in gene expression studies analysing tissue 
samples. Primers and concentrations used for beta actin assay: 200 nM 2253BACT_for and 
200 nM 2253BACT_rev (Table 4.4). Relative quantities (RQ) of chromosome-specific 
TERRA were calculated relative to 36B4 and beta actin according to the Pfaffl method [34].  
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Table 4.8 PCR conditions for 2p TERRA and 18p TERRA measurement 
 
PCR phase 
 
Temperature 
°C 
Time Number of 
cycles 
Initial denaturation 95 10 minutes 1 
Denaturation 95 15 seconds 40 
Annealing/extendsion 60 1 minute 40 
Melting curve 95 
60 
15 seconds 
1minute 
2 
2 
 
 
4.8 Absolute telomere length (TRF Assay) 
 
4.8.1 Preparation of DIG labelled probe for housekeeping gene 36B4  
 
For hybridization-probe preparation pCR II TOPO vector with cloned PCR fragment of 36B4 
was used. 
20 pg of plasmid DNA (0.2µg 1:10,000 diluted) were used as template for PCR with a PCR 
DIG Labeling Mix (Roche).  
 
10 µl 10 x Hot Start PCR buffer (Fermentas) 
10 µl DIG Labelling Mix (Böhringer-Mannheim, 1 558 706) 
 2 µl forward and reverse primer (10pmol) 
 1µl Hot Start Taq DNA polymerase (Fermentas) 
 6 µl MgCl2 (Fermentas) 
11.2 µl (20pg) template DNA 
59.8 µl ddH2O 
100 µl total volume 
 
PCR conditions used as described in table 4.6 for primers 36B4d and 36B4u. 
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4.8.2 Terminal restriction fragment length (TRF) analyses 
 
Telomere restriction fragment (TRF) analyses were done with TeloTAGGG Telomere Length 
Assay (Roche) according to the manufacturer’s instructions (Fig.4.4). 
 
 
Figure 4.4.  Steps of TRF analysis (from the manual TeloTAGGG Telomere Length Assay, Roche) 
 
Materials 
20% SDS:     
• 100g Sodiumdodecylsulfat 
• Fill with ddH20 to 500ml  
• Dissolve by heating (~ 68°C) 
• pH 7.2, if necessary adjust pH with a few drops of HCl 
 
20x SSC:    
• 175.3g NaCl 
• 88.2g sodium citrate 
• Dissolve in 800ml ddH2O 
• pH 7.4, If necessary adjust pH with 10N NaOH to 7.4 
• Fill with ddH2O to 1,000 ml  
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50x TAE:    
• 242 g Tris base 
• 57.1 ml glacial acetic acid 
• 100ml  0.5M EDTA pH =8 
• Fill to 1,000 ml with ddH2O and autoclave 
 
10x TAE: 
• dilute 50x TAE 1:5 with ddH2O 
 
Denaturation solution:  
• 43.83g NaCl 
• 10g NaOH 
• Fill to 500ml with ddH2O 
 
Neutralisation solution:   
• 87.66g NaCl 
• 30.25g Tris base 
• Fill to 500ml with ddH2O  
• Adjust pH to 7.5 with HCl 
 
Sufficient stringent washing buffer I:  
• 100ml 2xSSC 
• 0.5ml 2%SDS 
 
Sufficient stringent washing buffer II:  
• 10ml 2xSSC 
• 90ml H2O bidest 
• 0.5ml 2%SDS 
 
 
4.8.2.1 Digestion of DNA to analyse telomere length 
 
DNA was isolated from tissue samples and cell lines with the Maxwell System (Promega) as 
described in chapter 4.2.4. Furthermore, control DNAs for long and short telomeres from the 
TeloTAGGG Telomere Length assay (Roche) were available. 1µg of DNA was digested with 
HinfI and RsaI (each 20U/µl) for two hours at 37°C. These restriction enzymes cut the whole 
genomic DNA, except the telomeres and subtelomeric regions. 
 
4.8.2.2 Gel electrophoresis of digested DNA 
 
The digested DNA and the DIG-labeled DNA-marker were loaded on a 1% agarose gel 
(Seakem LE Agarose, Cambrex, USA) and run in 1x TAE for ~90 minutes at constant 90 Volt 
until the blue dye marker reaches the last third of the gel. After electrophoresis, the gel was 
stained for 15 minutes with Ethidium Bromide Solution (0.25µg/ml) and then washed with 
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ddH2O for about 10 minutes. Restriction efficiency was validated by EtBr DNA staining and 
DNA was visualized with FluorImager595 (Molecular Dynamics). 
 
4.8.2.3 Blotting 
 
The gel was incubated for 10 minutes with 0.25M HCl (till the colour of the dye turns to 
yellow) and washed with ddH2O. The gel was then incubated two times for 15 minutes with 
denaturation solution and again washed with ddH2O. Now, the gel is incubated for two times 
15 minutes with neutralisation solution (colour of dye turns back to blue). In the meantime, 
the blotting equipment is constructed according to Amersham Bio Sciences manual for 
capillary blotting (Fig.4.5). The gel is transferred on membrane over night. 
 
 
 
Figure 4.5 capillary blot. Transfer of DNA from agarose gel to a nylon membrane (Southern 
blot). Fig. was taken from: http://www.uni-greifswald.de/~genetik/GenetikII/5Analytik.pdf and 
modified. 
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4.8.2.4 UV-Crosslink 
 
After blotting, the semi-dry membrane is placed into the UV-crosslinker (Stratalinker UV 
Crosslinker, Stratagene) and the DNA was cross-linked two times at 1,200J. The cross-linked 
membrane is washed in 2xSSC.  
 
4.8.2.5 Hybridisation, chemoluminescence-detection and meanTRF calculation 
 
The membranes are placed in a glass tube of the hybridzation ofen (Shake `n´ Stack, Hybaid). 
Membranes are placed between meshes and loaded in the tube as described be the 
manufacturer and pre-hybridised for 30 minutes at 42°C in 18 ml of prehybridisation solution 
(TeloTAGGG Telomere Length assay, Roche). The membranes were then hybridised for 
three hours in 6.5 ml of freshly prepared hybridisation solution at 42°C.  
After hybridisation, the membrane is washed 2 times with sufficient stringent washing buffer 
I for 5 minutes at room temperature, and two times with sufficient prewarmed stringent 
washing buffer II for 15 minutes at 50°C. Membrane is transferred from tube to a tray and 
washed in 100 ml of washing buffer for 5 minutes. After washing the membrane in 100ml 
washing buffer, it is incubated in 100 ml of freshly prepared blocking solution. While the 
membrane is blocked, the antibody working solution is prepared.  
The blocking solution is then displaced by the antibody working solution and the membrane is 
incubated for 30 minutes at room temperature. Again wash the membrane two times for 15 
minutes in 200ml of washing buffer and incubate the membrane for 2-5 minutes at room 
temperature in detection buffer.  
Place the membrane on adsorbent paper and immediately place it on an opened transparent 
envelope bag. Put 40 drops (3ml) of substrate solution (CDP-Star) on the membrane and close 
the hybridisation bag, and incubate for 5 minutes at room temperature. Discard the excess of 
substrate solution and place it for 20 minutes on an X-ray film or on two staged films to get 
different grey scale saturations at once. 
 
After that the blot is visualised on Chemi-Smart 5100 analysing system (BioRad) and 
processed with ChemiCapt software. Mean TRF were determined in kbp with ImageQuant 5.0 
software (Molecular Dynamics) according to the manufacturer’s instructions of the 
TeloTAGGG Telomere Length Kit (Roche). The exposure picture of the blot was derived 
from ChemiSmart visualisation system as TIFF file and was loaded first in ImageJ 1.42 
software (NIH) for background correction (with rolling ball radius 200 pixel) and saved as 
16bit TIFF file.  
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This TIFF file was the reopened in ImageQuant 5.0 and a grid with 30 boxes is laid over 
every lane (including lane for the visualised molecular weight marker). The signal intensity is 
documented by volume report for the boxes. For each band of the molecular weight marker 
the length of migration is documented (for example the band corresponding the 21kb 
molecular weigth was found between box 8 and 9 at a box value of 8.2). By interpolation the 
molecular weight is calculated for every box of the lanes.  
And with the formula  
meanTRF = ∑ (ODi) / ∑ (ODi/Li) 
 
the mean TRF length is calculated. In this formula, ODi is the chemiluminescent signal and Li 
is the length of the TRF fragments at position i. This formula takes in account the higher 
signal intensities from larger TRF fragments because of multiple hybridisations of the 
telomere-specific probe [38]. 
 
4.9 Subtelomeric DNA methylation 
 
4.9.1 Bisulfite DNA conversion 
 
DNA conversion was performed with EpiTect Bisulfite kit (Qiagen) according to the 
manufacturer’s instructions. DNA isolated by TRIZOL and Maxwell method was used. Thaw 
DNA samples for Bisulfite DNA conversion. Dissolve Bisulfite Mix by adding 800 µl RNase-
free water and vortex until Bisulfite Mix is completely dissolved. The reactions are prepared 
in 250µl PCR tubes as described in Table 4.7. 
 
Table 4.7 Bisulfite conversion of DNA 
Component 
 
Volume per reaction 
(µl) 
DNA 1µg 
Rnase-free water variable 
Bisulfite Mix 85 
DNA Protect Buffer 35 
Total volume 140 
The combined volume of DNA and nuclease-free water must total 20µl, DNA concentration should be at least 
50ng/µl 
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The reaction is mixed and the colour of DNA protect buffer should turn from green to blue 
after addition, indicating the correct pH in the reaction mix. The bisulftite conversion is 
performed on a thermal cycler HYBAID Omn-E (GenXpress), using the following thermal 
profile (Table 4.8). 
 
Table 4.8 Thermal profile for bisulfite conversion of DNA 
 
DNA conversion was performed on HYBAID Omn-E thermal cycler (GenXpress) 
 
After conversion is complete, the converted DNA is cleaned up. Therefore, the reaction tubes 
are briefly centrifuged, and the reaction mix is transferred to a 1.5 ml tube (Eppendorf).  
560µl of loading buffer (Buffer BL) are added and mixed by vortexing. The whole mixture is 
transferred to an EpiTect spin column and all following steps are processed at RT.  
The column is centrifuged at maximal speed for 1 minute. The flow-through is discarded and 
500 µl of washing buffer (Buffer BW) are placed on the spin column. Column is again 
centrifuged at maximal speed for one minute, and the flow-through is discarded. 500 µl 
desulfonation buffer (Buffer BD) are loaded on the spin column and incubated for 10 minutes. 
Column is again centrifuged for 1 minute at maximum speed, and flow through is abolished. 
Then, the spin column is washed two times with washing buffer.  
Collection tube is replaced by a fresh one and spin column is centrifuged for 1 minute at 
maximum speed to remove residual liquids. DNA is eluted from the spin column with 20µl of 
elution buffer (Buffer EB) by placing the column on a 1.5ml tube. Tube is centrifuged for 1 
minute at 15,000 g. To increase the yield of DNA, a second time 20 µl of elution buffer is 
applied to the column and collected by centrifugation. At the end 40 µl of DNA is obtained, 
mixed, spinned down and stored at -20°C until use. 
 
 
 
Step Time 
minutes 
Temperature 
°C 
Denaturation 5 99 
Incubation 25 60 
Denaturation 5 99 
Incubation 85 60 
Denaturation 5 99 
Incubation 175 60 
Hold indefinite 28 
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4.9.2 PCR amplification of bisulfite converted DNA 
 
PCR was performed on iCycler (Bio-Rad) with a touchdown PCR protocol as described [24]. 
For methylation-specific PCR of the chromosome 2p-subtelomer and 18p-subtelomere region 
20 ng bisulfite converted DNA was used in a total of 20 µl reaction mixture containing 100 
nM primer HC_MP2 FWD and 100 nM of a modified primer HC_MP2 REV_S (Table 4.4 
and Table 4.5). 
 
Table 4.9 PCR conditions for amplification of bisulfite converted DNA 
 
*touch-down PCR protocol: annealing temperature reduced by 1°C at each cycle 
 
PCR fragments of 156 bp in size were purified by 3% agarose (Biozyme) gel electrophoresis. 
The extent of methylation was determined by ordered direct sequencing of PCR fragments by 
QIAGEN GmbH, Hilden, as follows:  
 
All sequencing reaction mixes were based on the BigDye™ 3.1 Terminator chemistry 
(Applied Biosystems). Template amounts of 5 ng per 100 bases of fragment-length and 10 
pmol primer per reaction were used. Reactions were cycled in a GeneAmp® PCR System 
9700 (Applied Biosystems) and purified using DyeEx™ (QIAGEN).  
 
Data collection was carried out on a 3730xl DNA Analyzer (Applied Biosystems) equipped 
with 50 cm capillary arrays and POP 7™ polymer. After data collection the raw data channels 
from the generated result-files (.ab1) were processed using custom-built software developed 
at QIAGEN. Data processing involved the compensation of the different migration-properties 
of the four dyes, baseline correction, peak detection and base-calling. For each base the area 
was calculated from the corresponding peak to measure the base's quantity.  
 
PCR phase 
 
Temperature 
°C 
Time Number of 
cycles 
Initial denaturation 94 5 minutes 1 
Denaturation 94 
62 ->52* 
30 seconds 
45 seconds 
10 
Annealing/extendsion 94 
62 
30 seconds 
45 seconds 
28 
Melting curve 72 5 minutes 1 
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Bases that correspond to variable positions of CpG-sites were identified by comparison of the 
obtained sequence with a reference sequence. The ratios of methylated versus unmethylated 
species were reported. Validation experiments have shown that the accuracy is in the range of 
±5 % when comparing differences obtained for the same CpG-site from different samples 
having a signal-to-noise ratio of 20 or above. 
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5 Results 
 
28 GBM, 6 AA and 12 DA tissue samples from patients with known diagnosis were analysed 
for telomere length. Furthermore, 6 non-tumour tissue samples from 2 patients and a subset of 
12 human tumour cell lines originated from astrocytomas plus one from each meduloblastoma 
and osteosarcoma were analysed.  
 
5.1 Results of DNA isolation 
 
DNA was isolated by two different methods, from Trizol and form Chaps remainders as 
described in Materials and Methods chapter 4.2.  
The two methods for isolating DNA were compared by quantifying the resulting DNA. This 
was done, using two different methods for quantifying DNA, NanoDrop ND-1000 
Spectrophotometer (Peqlab) and Qubit Fluorometer (Invitrogen, Fisher Scientific). DNA was 
isolated from parts of the same frozen tissue with comparable size. Tissue was cut semi-
frozen in pieces as described in Methods 4.2.1 Homogenisation of tissues. 
 
The results from 4 analysed tissues showed, that the amount of DNA isolated from Chaps 
remainder was up to the 1-3 fold, compared to DNA isolated from Trizol (Table 5.1).  
When the DNA isolated from Trizol was quantified, the results showed with Qubit 
fluorometer a strong decreased amount as compared to the Nanodrop measurement. The 
Quibit method recognizes exclusively intact dsDNA, while the photometer does not. Because 
of that, the amount of DNA isolated from Trizol was strong overestimated, potentially 
because of free nucleotides, which are measured by Nanodrop, but not with Qubit 
fluorometer. However, for DNA, isolated from Chaps remainders, the amount of DNA was 
similar or slightly higher, when quantified with Qubit fluorometer. Thus reflects a higher 
quality of intact dsDNA isolated from Chaps remainders as compared from Trizol. 
 
Furthermore, the amount of contaminating proteins and RNA was also determined with Qubit 
fluorometer in DNA samples. Proteins could not be detected in any of the DNA samples 
(detection limit of protein <12.5µg/ml). 260/280 ratio indicates higher amount of 
contaminating proteins in DNA samples isolated from Trizol (see Table 5.1). 
In contrast to proteins, RNA could be determined in all DNA samples. The ratio of RNA to 
DNA was calculated to be about 100-times higher, when the DNA was isolated from Chaps 
remainders with Maxwell DNA tissue DNA purification kit, when compared to Trizol 
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isolated DNA. This seems to be due to the lower amount on DNA in Trizol lysats, because the 
amount on RNA is in both methods of isolation very similar. 
When DNA was isolated from the Chaps remainder and from a piece of frozen tissue with 
Maxwell tissuec DNA purification kit, the amount of isolated DNA was also higher in Chaps 
remainders (up to the 2 fold). 
 
Table 5.1 Comparison of different methods of DNA isolation (Trizol or Chaps) and 
quantification (Nanodrop or Qubit) 
 nanodrop    Qubit   
Sample  
ng/µl 
total 
µg 
 
260/280 
 
ng/µl 
total 
µg 
RNA total 
µg 
RNA/DNA 
GBM21_T 183.14 9157 1.56 6.7 335 1.315 1:255 
GBM21_T 34.07 10221 1.74 47.2 14160 1.25 1:11328 
GBM20_T 360.14 18007 1.83 2.3 115 2.805 1:41 
GBM20_C 105.86 31758 1.86 120.2 36060 3.475 1:10377 
GBM28_T 33.34 1667 1.64 2.3 116 to low  
GBM28_C 74.85 22455 1.9 98.2 29460 2.685 1:10972 
GBM19_T 66.08 3304 1.75 3.1 156 1.765 1:88 
GBM19_C 31.36 9408 1.88 39.2 11760 1.41 1:8340 
For Nanodrop and Qubit fluorometer the concentration is given in ng/µl and the total amount of DNA is 
calculated. Trizol DNA was dissolved in 50µl of NaOH buffer and Qubit DNA was dissolved in 300µl of elution 
buffer (EB). 
T … Trizol;  
C … Chaps; 
 
Tumour cells require a telomere maintenance mechanism, usually provided by the enzyme 
telomerase, but some of telomerase negative tumour cells can maintain their telomeres by a 
mechanism known as alternative lengthening of telomeres (ALT), which is based on 
recombination events. It was one goal of this study, to measure the telomere length of 
astrocytoma tumour samples and astrocytoma cell lines (telomerase positive examples) and 
the osteosarcoma cell line Saos-2 (as an example for an ALT cell line). Saos-2 is a telomerase 
negative cell line and utilizes ALT mechanism. One hallmark of this mechanism is the 
extremely long and heterogeneous telomere length in contrast to cells that use telomerase 
activity. The telomere lengths were measured by terminal restriction fragment (TRF) analysis 
and by a quantitative real-time PCR assay as described in Materials and Methods.  
 
 
 64 
5.2 Telomere lengths ananlysis 
 
Telomere length was determined by a quantitative real-time PCR assay with primers tel1b 
und tel2b for amplification of telomeric TTAGGG–repeats (T), and with primers 36B4d and 
36B4u for comparision with a single copy gene 36B4 (S). PCR conditions are described in 
Table 4.4 of chapter Materials and Methods. Relative telomere length was determined as RQ 
value (T/S). First, telomere lengths of a subset of 14 tissue samples and 5 cell lines were 
analysed and compared with the two methods, terminal restriction fragment (TRF) analysis 
and quantitative real-time PCR. 
 
5.2.1 Terminal restriction fragment analysis 
 
Terminal fragment length analysis was performed with TeloTAGGG Telomere Length Assay 
kit (Roche) as described in detail in Methods. Genomic DNA isolated from cell lines and 
tumour tissue samples was digested with restriction enzymes RsaI and HinfI, size fractioned 
on agarose gel, stained with ethidium bromide and visualized on the FluorImager 595 (Figure 
5.1). As we tested, DNA isolated from Trizol was only partially digested, even when digested 
overnight in a larger volume (instead of 20 µl 100 µl total volume set up was applied). So we 
used Chaps remainders as described in literature [30] and isolated DNA with the automated 
Maxwell 16 tissue DNA purification system. This DNA could be completely digested, and 
was used for all TRF analysis done within this study. 
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a)                     b) 
 
  1      2      3      4     5      6     7      8      9     10     1     2      3      4      5     6      7      8      9   10 
Figure 5.1(a + b) Digestion of genomic DNA with restriction enzymes RsaI and HinfI. Samples with 1 µg 
DNA were analysed by 1% agarose gel electrophoresis, stained and visualized on FluorImager. 
(a) DNAs isolated from Trizol are digested only partially. Only the two control DNAs from the TeloTAGGG 
Telomere length kit are completely digested (lane 8 + 9), GBM samples isolated from Trizol are (Bitte immer 
die selbe Zeit nehmen!) only partially digested (lanes 2 - 7). Marker from Roche TeloTAGGG kit is loaded in 
lane 1 and 10.  
(b) DNAs isolated with Maxwell 18 tissue DNA purification kit are completely digested. Undigested (lanes 2, 4, 
6, 8) and digested DNA (3, 5, 7, 9) from the same tissue probe are loaded on the gel in adjacent lanes. Lanes 1 
and 10: markers 
  
Two control DNAs of the Telo TAAGGG kit (control-DNA low and control-DNA high) with 
known meanTRF lengths and a Digoxigenin- (DIG-)labeled DNA molecular weight marker 
were also loaded on the agarose gel (see Figure 5.2.a). For the two control-DNAs, included in 
the kit, the manufacturer gave a mean TRF length of 3.9 kb for control low DNA and 10.2 kb 
for control high DNA. 
 
After electrophoresis, gels were blotted, hybridised with a DIG-labelled telomere-repeat 
specific probe and detected with an anti-DIG antibody, linked to alkaline phosphatase. This 
phosphatase cleaves the applied substrate CDP star, leading to the production of light.  
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The results where visualized on Chemi-Smart 5100 analysing system (BioRad) and further on 
X-ray films.  
On first experimental blots, only cell culture cells were analysed (Figure 5.2). 
To test the sensitivity for the detection of TRF targets from the assay, a 1:5 dilution series of 
the included control high mean TRF DNA were applied in amounts of 760 ng, 200 ng and 40 
ng (figure 5.2). TRF signals with low amount of 40 ng DNA could be still detected, but the 
signal intensity was very weak.  
 
a)          b)         c) 
 
 
 
 
 
 
 
 
 
 
 
                                
                          1     2   3    4     5    6   7    8          9   10   11    1     2      3     4    5     6   7     8     9    10   11    12 
Figure 5.2 (a-c) Analysis of terminal restriction fragment (TRF) length for cell lines.  
(a) λ-DNA with EcoRI digested and indicated fragment length (included in the kit)  
(b) genomic DNA (isolated with Maxwell 16 tissue DNA purification kit) was digested with RsaI und HinfI and 
size fractioned on a 1% agarose gel, stained with ethidium bromide and visualized on FluorImager 595. 40 ng of 
control high (lane 1), 200 ng of control high (lane 2), 760 ng of control high (lane 3); control low (lane 4), HeLa 
(lane 5), Saos-2 DNA isolated from Trizol (lane 6), Saos-2 DNA isolated with Maxwell system (lane 7), λ-
Marker (lane 8), MR1 (lane 9), YT-BO (lane 10), KM-HY (lane 11)  
(c) Southern blot of digested genomic DNA. 40 ng of control high (lane 1), 200 ng of control high (lane 2), 760 
ng of control high (lane 3); control low (lane 4), HeLa (lane 5), Saos-2 DNA isolated from Trizol (lane 6), Saos-
2 DNA isolated with Maxwell system (lane 7), λ-Marker (lane 8), MR1 (lane 9), YT-BO (lane 10), KM-HY 
(lane 11) and λ-Marker (lane 12) 
 
In next experimental blots, DNA purified from tumour tissue samples were analysed (Figure 
5.3). One sample originates from a tumour grade II (DA), one sample from a tumour grade III 
(AA) and 14 samples are from tumours diagnosed with grade IV (GBM). 
As an additional control to test for proper digestion, one of the GBM probes was additionally 
applied without being digested before. The results of this control is shown on the gel and blot 
by an almost defined single band at 21 kb (Figure 5.3 a+b, GBM 11 on lane 15). The same 
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DNA probe was digested to a low molecular weight DNA smear (Figure 5.3a: GBM 11 on 
lane 16) and results on the blot lower than 21 kb TRF (Figure 5.3b: GBM 11 on lane 16). This 
control demonstrates the importance for testing of proper digestion to measure correct TRF 
signals. 
Both, the grade II and the grade III sample show long telomeres on the blot, but there are also 
GBM samples with long telomeres (see Figure 5.3 b, lanes 3, 5 and 16 GBM with long 
telomeres). 
a)                                                                                   b) 
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Figure 5.3(a+b) Analysis of the terminal restriction fragment (TRF) length for tissue samples.  
(a) Genomic DNA was digested with RsaI and HinfI (except lane 14 is undigested), size fractioned on a 1% 
agarose gel, stained with ethidium bromide and visualized on FluorImager. AA 1 (lane 1), GBM 4 (lane 2), 
GBM 23 (lane 3), GBM 2 (lane 4), GBM 27 (lane 5) GBM 25 (lane 6), GBM 20 (lane7), GBM 28 (lane 8), λ-
Marker 2µg (lane 9), DA 10 (lane 10), GBM 16 (lane 11), GBM 2 (lane 12), GBM 14 (lane 13), GBM 11 
undigested (lane 14), GBM 11 (lane 15), GBM 10 (lane 16), control low (lane 17), λ-Marker 4µg (lane 18) 
(b) TRF Southern blot result of DNA from tissue samples. AA 1 (lane 1), GBM 4 (lane 2), GBM 23 (lane 3), 
GBM 2 (lane 4), GBM 27 (lane 5) GBM 25 (lane 6), GBM 20 (lane7), GBM 28 (lane 8), λ-Marker 2µg (lane 9), 
DA 10 (lane 10), GBM 16 (lane 11), GBM 2 (lane 12), GBM 14 (lane 13), GBM 11 undigested (lane 14), GBM 
11 (lane 15), GBM 10 (lane 16), control low (lane 17), λ-Marker 4µg (lane 18) 
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Hybridisation of TRF-blots with a single copy gene probe for normalisation: 
A DIG-probe for a single copy gene was applied to test the hypothesis if this can detect RsaI 
and HinfI restriction fragments for proper normalisation of DNA amounts applied. 
 
          a                  b                 c            d       e              f 
 
Figure 5.4 Dot blot of DIG-labeled probe for gene 36B4 
Probe was prepared as described under methods and diluted 1:10 (a), 1.100 (b), 1:1,000 (c), 1:10,000 (d) in 
2xSSC, PCR mix before cycling (e) and 2xSSC as a negative control (f) were spotted on the membrane. 
 
A DIG-labelled probe for the housekeeping gene 36B4 was prepared. Dot blot was done to 
determine the efficiency of the DIG-labelling (Figure 5.4). Signals were detected at the 1:10 
and 1:100 dilutions. 
After the dot blot, the Southern blot (shown in Figure 5.3b) was rehybridized with this probe, 
but no signals were detected. This could be, because the amplicon for DIG-labeling is only 75 
bp long and includes 21 T nucleotides, and only every 20th thymidine nucleotide is 
stochastically DIG-labelled. That means that statistically only around one thymidine 
nucleotide per amplicon is carrying a DIG-label. 
This experiment can potentially be successfully repeated with more adequate labelled 
amplicons from single copy genes (e.g. beta actin, 800 bp in size). 
 
Mean TRF analyses of tumour tissue samples and cell lines are summarized inTable 5.2.  
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Table 5.2 MeanTRF length of tumour tissue samples and cell lines 
Sample meanTRF 
(kb) 
Sample meanTRF 
(kb) 
SAOS-2(C) 8.9 GBM 16 3.5 
SAOS-2(T) 5.7 GBM 20 5.6 
HeLa 3 GBM 23 12.3 
MR1 2.5 GBM 25 6.7 
KM-YH 4.8 GBM 27 9.5 
YT-BO 8.8 GBM 28 5.6 
GBM 2 4.8 AA1 25.4 
GBM 4 8.8 DA10 29.8 
GBM 10 17.2   
GBM 11 7.6 Control low 3.7 
GBM 14 6.7 Control high 10.6 
Results of terminal restriction fragment length analysis in astrocytoma tumor tissue samples and cell lines, 
including three astrocytoma cell lines MR1, KM-HY and YT-BO, cervical cancer cell line HeLa and 
osteosarcoma cell line SAOS-2. Cell lines are described in Materials and Methods. 
 
5.2.2 Real time PCR assay for measuring telomere length 
 
In a primary set up, three different thermal profiles were tested for the optimal measurement 
of relative telomere lengths on two GBM tumour samples. The first profil (60°C/1minute) 
was described recently in literatur [32]. The two other profiles were described in [31] for 
telomere amplification and amplification of 36B4, respectively. The three thermal profiles use 
different annealing temperatures and were tested for both the T and S assay (Table 5.3). The 
thermal profile with 60°C/1min showed the highest distance between Ct of sample and Ct of 
non-template control (NTC) for both T and S assays, so this thermal profile was used later to 
determine the relative telomere length by PCR. 
 
Table 5.3 Test of three thermal profiles for (T) and (S) PCR assay.  
PCR assay 60°C/1min 58°C/1min 54°C/2min 
 Ct     SD  Ct(NTC) ∆Ct Ct      SD  Ct(NTC) ∆Ct Ct     SD  Ct(NTC)  ∆Ct 
(T) Telomere                 15.3   0.25   29.7 14.4         13.4   0.11   29.8     16.4          13.3  0,14    25.4     12.1 
(S) 36B4                        22.0 0.14   33.7    11.7         22.4   0.06   33.3     10.9          22.2  0.20    33.1     11.0 
    
(T) Telomere                15.5   0.05    29.7   14.2         16.2  0.17    29.8     13.6          15.3  0.27    25.4     10.1 
(S) 36B4                       22.4 0.37    33.7   11.3         23.0  0.09    33.3     10.3          22.7  0.14    33.1     10.4 
*(1) and (7) are tumour samples of astrocytic brain tumours (GBM1 und GBM7).  
Ct … cycle threshold for the sample 
SD … standard deviation 
CtNTC … cycle threshold of non-template control 
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5.2.2.1 Determination of Efficiencies 
 
For telomere length analyses a real time PCR assay was established (primers and PCR 
conditions are described in chapter Materials and Methods).  
For (T) telomeric repeats and for (S) single copy or house keeping gene 36B4 the efficiency 
(E) was determined by standard curve experiments. DNA of plasmid pSP73 containing an 
insert with 120 telomeric repeats (800bp) were diluted in a 1:1 dilution series for template of 
the T standard curve. Similarily, plasmid pCRII-TOPO with cloned 36B4 amplicon was used 
for the S standard curve.  
Number of molecules for standard curve are calculated [31], and for this purpose, conversion 
of pg of DNA to mol is done with DNA/RNA/Protein/Chemical Molecular Weight Calculator 
(http://www.changbioscience.com/genetics/mw.html), results given in table 5.4.  
 
Table 5.4 Dilution series for standard curves 
 Plasmid DNA 
(pg) 
pSP73_tel 
(molecules) 
pCRII-TOPO_36B4 
(molecules) 
1st step 10 298564887399 352961501992 
2nd step 5 149282443699 176480750996 
3rd step 2.5 74641221850 88240375498 
4th step 1.25 37320610925 44120187749 
5th step 0.625 18660305462 22060093875 
Steps in dilution series are 1:1 dilutions of plasmid DNA and nuclease-free water 
Number of molecules for pSP73 with insert of telomeric repeats and  
pCRII-TOPO vector with inserted 36B4 gene are calculate 
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(a)                                                                   (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 (a+b) Standard curve for house keeping gene 36B4 measured on ABI 7000 PCR system  
(a) standard curve for 36B4 and  
(b) amplification plot  
 
 
(a)                                                                               (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 (a+b) Standard curve for telomeric repeats on ABI 7000 PCR system 
(a) standard curve for telomeric repeats and  
(b) amplification plot  
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(a)                                                                      (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 (a+b) Standard curve for house keeping gene 36B4 on ABI 7500 Fast PCR system (with  
standard PCR program) 
(a) standard curve for 36B4 and  
(b) amplification plot  
 
(a)                                                                        (b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 (a+b) Standard curve for telomeric repeats on ABI 7500 Fast PCR system (with standard PCR 
program)   
(a) standard curve for telomeric repeats and  
(b) amplification plot 
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(a)                                                                      (b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 (a+b) Standard curve for house keeping gene 36B4 on ABI 7500 Fast PCR system (with Fast 
program)  
(a) standard curve for 36B4 and  
(b) amplification plot 
 
(a)                                                                       (b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 (a+b) Standard curve for telomeric repeats on ABI 7500 Fast PCR system (with Fast program )  
(a) standard curve for 36B4 and  
(b) amplification plot 
 
Standard curves showed, that amplification of gene 36B4 is not very efficient, when amplified 
with standard program on 7500 Fast Real-Time PCR system (74%). 
All other efficiencies were above 80% (for results see table 5.5).  
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Table 5.5 Efficiencies for telomeric repeats and 36B4 tested on different systems 
  Slope R2 Efficiency 
(%) 
Tm 
(°C) 
7000 tel 3.535 0.946 94 79.3 
 36B4 3.506 0.937 95 78.2 
7500 st          tel 2.281 0.729 146 78.1 
 36B4 4.513 0.949 74 78.1 
7500 fast tel 4.118 0.830 81 77.4 
 36B4 3.314 0.971 100 76.1 
Efficiencies on different systems and different chemistries (AB7000, AB7500 standard PCR, AB7500 fast PCR) 
were tested for single copy or house keeping gene 36B4 (S) and telomeric repeats (T).  
 
5.2.2.2 Measurement of relative telomere length 
After detection the efficiency of the assays, the relative telomere lengths were determined as 
relative quantity (RQ) values normalized to the single copy gene 36B4. Real time PCR assay 
for measuring telomere length was evaluated manually with a threshold cycle of 0.2 and 
baseline starts at Ct = 6 and ends at Ct = 15.  
The baseline in the amplification plot is a line fit to the fluorescence levels during the initial 
stages of PCR, when there is little change in fluorescence signal. The threshold cycle (Ct) is 
the PCR cycle number at which the fluorescence meets the threshold in the amplification plot.  
Assay with primers tel1b and tel2b were tested on PAGE in Figure 5.11 and later run in 
triplicates. A smear with multiple tel products appears on gel. In contrast, the NTC developed 
a single product size (potentially a primer dimer) at late Ct values. If one of three Ct values 
showed a standard deviation (SD) > 0.5 it was excluded form the analysis. Assay with primers 
36B4d and 36B4u were run in duplicates, and samples with SD > 0.5 were repeated. 
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a)                                                                                b) 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 (a+b) Amplicon of tel primers  
(a) show the amplification plot with number of cycles on the x-axis and Delta Rn on the y-axis  
(b) show the melting curve of tel amplicons with the temperature on the x-axis and a PAGE gel with a 50 bp 
DNA ladder (lane 1), the tel amplicon (lane 2) and the non-template control (lane 3) 
 
Primers for gene 36B4 were tested in silico with the CloneManager program by aligning them 
against the genomic sequence of the 36B4 gene. Sequence was taken from NCBI entry with 
the accession number NC_000012.11 (Figure 5.12). 
 
 
Figure 5.12 Aligning of primers 36B4u and 36B4d to the genomic sequence of gene 36B4 in CloneManager 9 
program (Primers are used for determining relative telomere length and expression of overall TERRA and 2p- 
and 18pTERRA) 
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For an additional test, the amplicon of gene 36B4 was analysed by PAGE. The amplicon 
shows the expected length of 75 bp and no product was detected in the non template control 
probe (Figure5.13). 
 
(a)                                                                 (b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 (a+b) Amplicon of 36B4 primers  
(a) shows the amplification plot  
(b) shows the melting curve of 36B4 amplicons and a PAGE gel with a 50 bp DNA ladder (lane 1), the 36B4 
amplicon (lane 2) and the non-template control (lane 3). 
 
 
For statistical analyses, RQ values were imported into GraphPad Prism 5. First, RQs were 
tested for normal distribution (D’Agostino and Person omnibus Test, Kolmogorow-Smirnov- 
und Shapiro-Whilk Test).  
RQ values were than tested with the Mann-Whitney test for significant differences in the 
median of different groups (e.g. tumour grades).  
 
RQs for telomere lengths are shown in Figure 5.14 for GBMs, DAs, AAs, non-tumor tissue 
and cell lines (10 derived from astrocytomas, 1 from a primary osteosarcoma and one from a 
medulloblastoma). RQ values were related to the median of non-tumour tissue. Tumour 
tissues and cell lines demonstrate 7.6 to 32.3-fold increase in relative telomere length. The 
shortest telomere lengths were observed in non-tumour tissues and sporadic in single 
astrocytomas (DA5, RQ=0.36 and GBM9, RQ=0.5) and cell lines (MGC, RQ=1.04). Cell 
lines showed high telomere length comparable to low grade II and III tumours. 
RQ values of telomere length demonstrate to be significantly increased (p=0.0014 for AA and 
p=0.0033 vor DA) in tumours with grade II and grade III (DA + AA) when compared to high 
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grade tumours (GBM), but there was no significant difference between grade II and grade III 
(Figure 5.14). 
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Figure 5.14 RQs for telomere length obtained with quantitative real-time PCR assay.  
RQ (T/S) values were related to the median of non-tumour tissues (epileptic foci) and were visualized log10 
scaled on a grouped scatter blot. Lines within a group of points represent median. Tumour and non-tumour tissue 
samples are characterized by a filled circle. Astrocytoma cell lines are marked with open circles, Daoy 
(medulloblastoma) is marked by a black triangle and Saos-2 is marked with an x. Median over all samples is indicated by the 
dashed line. ** = p<0.01 by Mann-Whitney test. 
 
The resulting RQ values from Figure 5.14 and the mean TRF values in kb from 13 tissue 
samples and 5 cell lines (table 5.1) were compared. Only tissues were tested for linear 
correlation and GBM was excluded because of problems for quantification in Real time PCR.  
RQ values are generally not normal distributed (tested by D´Agostino-Pearson, Shapiro-Wilk 
and Kolmogrov-Smirnov test) and showed no normal distributrion. Both types of values were 
transformed by decimal logarithm. In this way the values become a normal distribution, and 
were analysed by Pearson correlation (Figure 5.15). Linear regression analyses results a 
fitting line: [log] TRF = 0.6595 ± 0.2416x ([log] RQ) + 0.3850 ± 0.2176 with R2 = 0.4271 and 
P = 0.0212. With this formula, measured RQ values obtained by PCR can be converted in 
absolute mean TRF values. 
 
 
 
 
AA vs. GBM 
DA vs. GBM 
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Figur 5.15 Correlation of meanTRF and and RQs of quantitative real-time PCR assay.  
Both, meanTRFs and RQs are log10 transformed before linear correlation by Pearson. A weak but significant 
correlation between the results of the two different methods is shown. Only tissue samples were tested for linear 
correlation. GBM27 was excluded because of problems with quantification in Real time PCR). 
 
Next, with the formula the mean TRF values were calculated from all RQ data analysed 
(Table 5.6 a + b). Calculated TRF values of the groups were summed up by calculation of 
mean and standard deviation. The absolute telomere lengths based on mean TRF values of the 
groups (mean±standard deviation in kb) were compared. Telomere lengths increased in both 
grade II and III tumours DA (21.6 ± 14.9 kb) and AA (17.4 ± 4.5 kb), and in cell lines (18.4 ± 
10.7 kb) as compared to GBM (8.8 ± 4.0 kb) and non-tumour tissue (3.1± 2.5 kb).  
 
Tumours acquire an immortal phenotype with a telomere maintenance mechanism (TMM). 
Telomere length is a criterion to differ between TMM by either the ribonucleoprotein enzyme 
telomerase or a recombination-based alternative lengthening of telomeres (ALT) mechanism, 
the latter was found to be a prognostic indicator for patients with glioblastoma multiforme 
[39]. Criteria for alt are no telomerase activity and a telomere length > 17kb.[40] 
In this study results of telomere length measurement show that DA and AA show a mean 
telomere length >17kb and no telomerase activity. So DA and AA could be ALT, in contrast 
to GBM, which have a mean telomere length of 8.8 kb and 50% (14 of 28) of them show 
telomerase activity. Telomerase activity was determined in a former study (diploma thesis of 
Sibylle Pramhas). 
 
 
 
 
0.0 0.5 1.0 1.5 2.0
0.0
0.5
1.0
1.5
2.0
0212.0
427.0
2176.03850.0*2416.06595.0
2
=
=
±+±=
P
R
xy
[LOG] RQ
[L
O
G
]m
e
a
n
T
R
F
(k
b
p
)
 79 
Table 5.6a Telomere length of tissues 
tissue # mean TRF (kb) RQ calculated TRF  
(kb)        mean    SD 
GBM 1  8.41 9.9           8.8      4.0    
 2 4.8 4.75 6.8 
 3  4.58 6.6 
 4 8.8 5.04 7.1 
 5  8.17 9.7 
 6  7.46 9.1 
 7  19.32 17.1 
 8  6.21 8.1 
 9  0.08 0.5 
 10 17.2 26.96 21.3 
 11 7.6 3.67 5.7 
 12  7.00 8.8 
 13  5.34 7.3 
 14 6.7 3.02 5.0 
 15  7.25 9.0 
 16 3.5 5. 25 7.2 
 17  5.63 7.6 
 18  7.55 9.2 
 19  16.62 15.5 
 20 5.6 8.96 10.3 
 21  8.97 10.3 
 22  10.12 11.2 
 23 12.3 9.60          10.8 
 24  6.55 8.4 
 25 6.7 6.59 8.4 
 26  4.09 6.1 
 27 9.2 1.33 2.9 
 28 5.6 5.25 7.2 
AA 1 25.4 22.33 18.8              17.4         4.5 
 2  16.21         15.2 
 3  8.90          10.3 
 4  22.17         18.7 
 5  20.67         17.9 
 6  31.6           23.7 
DA 1  77.68         42.8              21.6       14.9      
 2  19.00          16.9 
 3  20.83          18.0 
 4  5.55 7.57.5 
 5  0.36 1.2 
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tissue # mean TRF (kb) RQ calculated TRF  
(kb)        mean    SD 
 6  82.34 44.5 
 7  44.04          29.5 
 8  10.70          11.6 
 9  44.73          29.8 
 10 29.8 7.74 9.4 
 11  8.15 9.7 
 12  66.05          38.5 
HC 1  1.34 2.9          3.1         2.5 
 2  0.45 1.4 
CO 1  0.66 1.8 
 2  0.22 0.9 
TM 1  5.86 7.8 
 2  1.71 3.5 
GBM     glioblastoma multiforme (grade IV) 
AA        anaplastisc astrocytoma (grade III) 
DA        diffuse astrocytoma (grade II) 
HC        Hippocampus 
CO        Cortex  
TM        temporal mark  
* non-tumour tissues are taken from these brain regions from two patients 
 
 
Table5.6b Telomere length of cell lines 
tissue cell line mean TRF (kb) RQ calculated TRF  
(kb)             mean           SD              
Astrocytoma CCF-STTG1  n.a. n.a               18.4          10.7 
 DBTRG/05MG  26.60 21.1 
 KG-MH  20.44 17.8 
 KM-YH 4.8 34.46 25.1 
 LN-140  23.11 19.3 
 MGC    1.04   2.5 
 MR1 2.5   9.60 10.8 
 T98G  10.96 11.8 
 U-373 MG  16.52 15.4 
 YT-BO 8.8 83.69 45.0 
 YU-PM  11.37 12.1 
 Hs683    
Medulloblastoma Daoy  13.86 13.7 
Osteosarcoma SAOS-2 8.9 37.46 26.5 
Tables 5.6b show the meanTRF length in kb (determined on Southern blots) and the RQs from the quantitative 
real-time PCR assay of cell lines. Additionally, mean TRFs were calculated by interpolation with a formula as 
described in the text. 
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5.3 Real-time PCR assay for measuring TERRA expression  
 
Overall telomere expression was determined by the same PCR assay as for telomere length 
measurement. Reverse transcribed RNA termed as cDNA was used instead of genomic DNA 
for expression analysis of telomeric repeats.  
 
In contrast to the assay for amplifying the telomere repeats for overall TERRA, I established 
assays with specific primers from the subtelomeric region for the analyses of TERRA from 
chromosomal ends 2p and 18p. The calculated and expected length for the amplicons for 2p 
TERRA and 18p TERRA are 109 bp and 149 bp, respectively. 
Primer sequences were tested in CloneManager9 by aligning them against the genomic 
sequences of subtelomeric regions of chromosome 2p and 18p (Figure 5.16 and 5.17, 
respectively). Genomic sequences were taken from MapViewer Homo sapiens, build 37.1. 
 
 
Figure 5.16 Aligning of primers chr2_590 and chr2_738 to the genomic sequence of subtelomeric region of 
chromosome 2p. Results of the primer test with CloneManager 9 program is presented. Lower panel: line 
represents 5kbp of sub-telomeric sequence with the telomere positioned on the right (5’) site, primers for 
expression of 2pTERRA and for methylation-specific PCR of subtelomeric region of chromosome 2p are shown, 
note: the hypothetical transcription start site is located between both amplicons. 
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Figure 5.17 Aligning of primers chr18_617 and chr18_725 to the genomic sequence of subtelomeric region 
of chromosome 18p in CloneManager 9 program. Lower panel: line represents 5kbp of sub-telomeric sequence 
with the telomere positioned on the right (5’) site, primers for expression of 2pTERRA and for methylation-
specific PCR of subtelomeric region of chromosome 2p are shown, note: the hypothetical transcription start site 
is located between both amplicons. 
 
Primers were tested by real-time PCR, and amplicons were analysed by PAGE (Figure 5.18 
and 5.19). Amplicons showed the expected length of 149 and 109 bp, respectively. Both NTC 
controls gave no signal during amplification and on the temperature melting profile and 
consequently on the gel.  
     (a)                                                                  (b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 (a+b) 2p TERRA  
(a) shows the amplification of 2p TERRA in an astrocytoma tissue sample, and  
(b) shows the melting curve of the PCR product; the amplicon was also loaded on a PAGE-gel to show the 
specifity of the assay: non-template control (lane 1), amplicon from genomic DNA (lane 2) and from reverse 
transcribed DNA (lane 3). 
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    (a)                                                                                (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.19 (a+b) 18p TERRA  
(a) shows the amplification of 18p TERRA in an astrocytoma tissue sample, and  
(b) shows the melting curve of the PCR product; the amplicon was also loaded on a PAGE-gel to show the 
specifity of the assay: non-template control (lane 1), amplicon from genomic DNA (lane 2) and from reverse 
transcribed DNA (lane 3). 
 
 
RQ values obtained with this assays, were determined relative to median of non-tumour 
tissues and to expression levels of ribosomal gene 36B4 (Table 5.5 a + b). If 2p or 
18pTERRA was not detected in real-time PCR, a Ct of 35 was assumed to calculate the RQ 
for these samples. 
Experiments for overall TERRA and 2pTERRA and 18pTERRA run in 7500 Fast Real-Time 
PCR system (Applied Biosystems) and to analyse results, they were combined in a study in 
ABI SDS Software version2.2. 
For overall TERRA, 6 96-well plates were combined in a study. 7 wells showed high SD, 8 
wells showed no amplification and 5 were marked as ouliers in replicate groups (Table 5.10) 
For 2p TERRA and 18pTERRA, 17 96-well plates were in the study. 56 wells showed no 
amplification of the sample. In 32 wells the software was not able of identify an exponential 
region of amplification. 23 wells were marked for high SD (Table 5.11). 
 
By comparison of mean Ct of the two housekeeping genes, it can be seen, that in allmost all 
samples tested (cell lines and tissues), 36B4 is 2 – 3 Ct earlier compared to b-Actin (Table 
5.7a+b).  
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Table 5.7a Comparison of two house keeping genes in cell lines 
tissue cell line 36B4* b-Actin* 
Astrocytoma CCF-STTG1 15.2 16.5 
 DBTRG/05MG 16.0 17.8 
 KG-MH 14.3 16.4 
 KM-YH 15.7 17.1 
 LN-140 14.6 15.2 
 MGC 14.4 16.3 
 MR1 15.7 16.4 
 T98G 14.9 16.4 
 U-373 MG 15.6 17.3 
 YT-BO 14.8 16.7 
 YU-PM 14.1 17.5 
 Hs683 14.3 17.1 
Medulloblastoma Daoy 14.5 17.2 
Osteosarcoma SAOS-2 14.7 17.5 
*mean Ct for 36B4 and b-Actin are given 
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Table 5.7b Comparison of two house keeping genes in tissues 
tissue # 36B4* b-Actin* 
GBM 1 15.5 19.4 
 2 14.1 16.9 
 3 15.5 17.9 
 4 16.3 18.0 
 5 18.2 19.9 
 6 16.9 19.1 
 7 15.1 17.2 
 8 15.7 17.9 
 9 16.5 18.8 
 10 15.8 17.8 
 11 15.4 18.2 
 12 15.9 18.9 
 13   
 14 16.0 19.4 
 15 16.5 18.7 
 16 16.4 19.1 
 17 15.6 17.8 
 18 16.1 18.7 
 19 17.6 19.7 
 20 14.8 17.4 
 21 14.2 16.5 
 22 15.6 18.0 
 23 15.6 17.6 
 24 14.5 18.1 
 25 15.2 18.1 
 26 16.2 19.4 
 27 18.1 18.9 
  28 15.7 17.9 
AA 1 15.8 17.9 
 2 17.2 19.1 
 3 17.2 18.2 
 4 19.6 21.2 
 5 18.1 20.1 
  6 18.4 18.7 
 DA 1 17.5 18.2 
 2 18.3 19.4 
 3 16.0 17.0 
 4 17.3 18.7 
 5 17.4 18.7 
 6 17.4 19.2 
 7 17.8 19.1 
 8 16.8 19.3 
 9 16.8 19.1 
 10 15.5 18.8 
 11 17.2 18.3 
  12 15.6 17.7 
HC 1 17.6 20.8 
 2 16.2 20.7 
CO 1 17.2 21.5 
 2 16.1 20.2 
TM 1 18.2 21.8 
  2 17.6 20.8 
*mean Ct for 36B4 and b-Actin are given 
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Table 5.8a Overall, 2p and 18pTERRA expression in tissue samples  
   compared to 36B4    compared to beta-actin  
tissue # overall chr.2p chr.18p chr.2p chr.18p 
GBM 1 0.0018 0.0637 0.3223 0.0407 0.2052 
 2 0.0004 0.0259 0.0626 0.0360 0.0867 
 3 0.0091 0.1404 0.6851 0.2467 1.1981 
 4 0.0028 0.1682 0.1785 0.4988 0.5269 
 5 0.0299 1.1464 0.6823 3.4295 2.0324 
 6 0.0010 0.1984 0.2333 0.4139 0.4846 
 7 0.0007 0.0351 0.0309 0.0780 0.0684 
 8 0.0316 0.0896 0.2916 0.1854 0.6008 
 9 0.0007 0.0235 0.2391 0.0463 0.4685 
 10 0.3971 1.2572 3.1678 2.9823 7.4822 
 11 0.0038 0.1285 0.2961 0.1843 0.4229 
 12 0.0043 0.3358 0.0066 0.4315 0.0084 
 13 0.0108 1.2479 3.0662 1.2558 5.2062 
 14 0.0028 0.1195 0.0651 0.1118 0.0607 
 15 0.0045 0.3632 0.0026 0.7353 0.0053 
 16 0.0003 0.0807 0.0055 0.1143 0.0078 
 17 0.0040 0.2383 0.0323 0.5246 0.0708 
 18 0.0080 0.4967 0.3773 0.8001 0.6051 
 19 0.0065 0.5540 0.2768 1.1721 0.5832 
 20 0.0043 0.2395 0.3508 0.3644 0.5315 
 21 0.0002 0.0331 0.1490 0.0640 0.2871 
 22 0.0030 0.0463 0.4562 0.0825 0.8099 
 23 0.0025 0.0437 0.0627 0.1046 0.1494 
 24 0.0005 0.0241 0.0873 0.0195 0.0704 
 25 0.0004 0.3415 1.7163 0.4477 2.2402 
 26 0.0034 0.1676 1.0869 0.1773 1.1451 
 27 0.0022 0.3346 0.1429 1.9212 0.8170 
  28 0.0867 0.1801 0.0356 0.3619 0.0713 
AA 1 0.0137 0.0436 0.0416 0.0958 0.0911 
 2 0.2444 0.3075 2.2598 0.7956 5.8207 
 3 0.0027 0.0894 0.5318 0.4560 2.7016 
 4 0.1081 0.2245 1.8099 0.7085 5.6863 
 5 0.0060 1.0708 0.0740 2.6237 0.1805 
  6 0.0751 0.1750 0.9934 1.2900 7.2930 
DA 1 0.4666 0.4087 0.1403 2.4263 0.8290 
 2 0.0465 0.1205 0.0919 0.5488 0.4165 
 3 0.0488 0.1067 0.1020 0.5076 0.4830 
 4 0.3968 0.3341 0.0653 1.1545 0.2338 
 5 0.1140 0.2369 0.1658 0.9186 0.6403 
 6 0.1251 0.8444 0.0604 2.3520 0.1674 
 7 0.0266 0.1369 0.6285 0.5185 2.3700 
 8 0.0004 0.4083 0.1604 0.6555 0.2564 
 9 0.1549 0.1006 0.4152 0.1985 0.8155 
 10 0.1120 0.7170 2.4352 0.7061 2.3880 
 11 0.0274 0.7585 1.4806 3.3682 6.5464 
  12 0.0862 0.0413 0.3637 0.0946 0.8290 
HC 1 0.8806 0.5457 0.7815 0.5603 0.7989 
 2 0.4405 5.0213 3.0735 2.0399 1.2433 
CO 1 3.8261 0.2920 0.0844 0.1415 0.0407 
 2 1.4357 0.2350 0.0910 0.1348 0.0519 
TM 1 0.2989 6.4059 26.7621 5.0147 20.8595 
  2 1.1194 1.4543 1.2185 1.4397 1.2011 
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Table 5.8b Overall, 2p and 18p TERRA expression in cell lines 
tissue cell line overall chr.2p chr.18p chr.2p chr.18p 
  relative to 36B4   relative to b-actin  
Astrocytoma CCF-STTG1 0.0041 0.0022 0.0350 0.0061 0.3307 
 DBTRG/05MG 0.0179 0.0172 0.0191 0.0372 0.0412 
 KG-MH 0.0075 0.0095 0.1347 0.0343 0.4868 
 KM-YH 0.0092 0.0023 0.0128 0.0217 0.0782 
 LN-140 0.0030 0.0117 0.0124 0.0297 0.1169 
 MGC 0.0239 0.0062 0.0103 0.0354 0.0590 
 MR1 0.0036 0.0053 0.0068 0.0499 0.0223 
 T98G 0.0037 0.0218 0.0247 0.0672 0.2338 
 U-373 MG 0.0021 0.0007 0.0163 0.0017 0.1543 
 YT-BO 0.0088 0.0153 0.0105 0.0143 0.0097 
 YU-PM 0.0327 0.0410 0.0409 0.0583 0.0578 
 Hs683 0.0319 0.0200 0.0250 0.0282 0.0350 
Medulloblastoma Daoy 0.0186 0.0697 0.0775 0.2727 0.3017 
Osteosarcoma SAOS-2 0.2107 0.1134 0.0262 0.1577 0.0362 
Table 5.8a and 5.8b show RQ-values of expression of overall TERRA, 2pTERRA and 18pTERRA. RQs for 
overall TERRA are relative to 36B4; 2pTERRA and 18pTERRA are relative to 36B4 and b-actin. 
If 2p or 18pTERRA was not detected in Real-time PCR, a Ct of 35 was assumed to calculate the RQ for these 
samples. 
GBM     glioblastoma multiforme (grade IV) 
AA        anaplastisc astrocytoma (grade III) 
DA        diffuse astrocytoma (grade II) 
HC        Hippocampus* 
CO        Cortex* 
TM        temporal mark* 
* non-tumour tissue is taken from these brain regions from two patients 
 
 
RQ values (related to 36B4) were presented grouped on a scatter blot with log10 scale (Figure 
5.20 (a-c). Overall TERRA declined gradually from non-tumour tissues over DA, AA to 
GBM. Overall TERRA expression was decreased 14 and 31-fold in GBM compared to AA 
and DA (p<0.05), respectively. 2p TERRA showed the same trend like overall TERRA to 
decline gradually, whereas 18p TERRA did not show to follow this trend. 
From all cell lines analysed, SAOS-2 showed for 2p TERRA and overall TERRA the highest 
expression level. But not for 18p TERRA, the expression level was comparable to the other 
cell lines analysed.  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 (a) Expression of overall TERRA in brain tissue samples and astrocytoma cell lines and also 
Saos-2. RQ related to 36B4.  
(a) Overall TERRA shows a decrease over grades from non-tumour tissue, over low grade tumour samples to 
glioblastomas multiforme. Saos-2 shows the highest overall TERRA expression in cell lines. 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 (b) Expression of 2pTERRA in brain tissue samples and astrocytoma cell lines and also Saos-2. RQ 
related to 36B4.  
Expression of 2p TERRA: Comparable to overall TERRA expression, 2p TERRA expression is declining with 
the grade of tumour. Non-tumour tissue shows the highest expression of 2p TERRA- Saos-2 shows the highest 
level on 2p TERRA expression for cell lines.  
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c) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 (c) Expression of 2pTERRA in brain tissue samples and astrocytoma cell lines and also Saos-2. RQ 
related to 36B4.  
18p TERRA shows no correlation with grade. Brain tumour cell lines are labelled with open circles, whereas 
Saos-2 is shown by an x. 
 
Linear correlation performed on log transformed data of the astrocytic brain tumour samples 
revealed a link between TERRA expression and telomere length. Overall TERRA levels 
correlated weak but significantly with TERRA of 2p (Pearson r = 0.5251value = 0.0021) and 
18p (Pearson r = 0.3407 P value = 0.0134) chromosomal ends and with RQ of telomere length 
(Pearson r = 0.4052, P value = 0.0006) as shown in Figure 5.21 a – c. 
 
 
 
Figure 5.21(a) Correlation test and linear regression between telomere length and expression levels of 
overall TERRA in astrocytoma tissue samples. 
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Figure 5.21(b) Correlation of 2pTERRA with overall TERRA (only tissues are used for correlation) 
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Figure 5.21(c) Correlation of 18p TERRA with overall TERRA (only tissues are used for correlation) 
 
To demonstrate the specifity of the new designed assays for 2pTERRA and 18pTERRA, 
cDNA of one GBM tumour tissue was PCR amplified and PCR products where cloned in 
pCRII TOPO vector by TOPO TA cloning.  
Plasmids were isolated from 3 blue clones (supposed to contain inserts) from 2pTERRA and 
18pTERRA products with WIZARD® Plus SV Miniprep DNA Purification System 
(described in Materials and Methods, chapter 4.5). Plasmids were analyzed by restriction with 
EcoRI to cut out the cloned insert from the vector (Figure 5.22a).  
For a second test, isolated plasmids were amplified by PCR with primers chr2_590 + 
chr2_738 and chr18_617 + chr18_725. Two of the isolated clones of 2pTERRA and all 3 
clones of 18pTERRA did show the expected insert size, and only one clone of 2pTERRA did 
not or failed PCR amplification (Figure5.22b). 
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        1   2   3   4   5   6     7     8   9   10   11   12   13         1     2   3    4    5    6    7    8    9   10   11 
Figure 5.22 (a+b) Agarose gel for analysing clones of 2pTERRA and 18pTERRA 
(a) Plasmids were digested with EcoRI and loaded on a 5% PAGE-gel; 2p_clone1digested (lane1); 
2p_clone1undigested (lane2); 2p_clone2 digested (lane3); 2p_clone2 undigested (lane4); 2p_clone3 digested 
(lane5); 2p_clone3 undigested (lane6); 50bp Marker (lane 7); 18p_clone1digested (lane8); 
18p_clone1undigested (lane9); 18p_clone2 digested (lane 10); 18p_clone2 undigested (lane 11); 18p_clone3 
digested (lane 12); 18p_clone3 undigested (lane 13); 
(b) Plasmids are PCR amplified with primers chr2_590 and chr2_738 for clones of 2pTERRA and chr18_617 
and chr18_750 for clones of 18pTERRA; 50bp Marker (lane1); 2p_clone 1 (lane 2); 2p_clone2 (lane 3); 
2p_clone3 (lane 4); NTC_primers chr2_590 and chr2_738 (lane 5); 18p_clone 1 (lane 6); 18p_clone2 (lane 7); 
18p_clone3 (lane 8); NTC_primers chr18_617 and chr18_750 (lane 9); 
Only 2p_Klon3 shows not the correct insert, all other plasmid carry the expected insert. 
 
One clone of 2pTERRA and one clone from 18pTERRA were sequenced by VBC genomics, 
and the obtained sequences where aligned in Clonemanager 9 program against the sequences 
of the subtelomeric region of chromosome 2p and 18p, respectively (Figure 5.23). The 
sequences were 100 percent identical. 
Genomic sequence for the alignment was taken from MapViewer homo sapiens, build 37.1 
for both subtelomeric regions (chromosome 2p and 18p). 
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Figure 5.23a Sequencing results for 2pTERRA. Sequence similarity was tested in Clone Manager 9 by DNA 
alignment. Genomic sequence was taken from MapViewer homo sapiens, build 37.1 
Non-matching bases are coloured 
Top panel … part of sequencing result from VBC Genomic (nt100 – 200, nt100 is start of the 2pTERRA 
sequence, as can be seen in the button panel, sequenes start to be identical)  
Button panel … alignment of genomic sequence (nt 590 – 738) shows sequences are 100% identical  
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Figure 5.23b Sequencing results for 2pTERRA. Sequence similarity was tested in Clone Manager 9 by DNA 
alignment. Genomic sequence was taken from MapViewer homo sapiens, build 37.1 
Non-matching bases are coloured 
Top panel … part of sequencing result from VBC Genomic (nt100 – 200, nt100 is start of the 18pTERRA 
sequence, as can be seen in the button panel, sequenes start to be identical)  
Button panel … alignment of genomic sequence (nt 617 – 725) shows sequences are 100% identical  
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Table 5.10 QC-Summary of overall TERRA study 
 
Biological Replicate Reference 
Sample Epi  
Chemistry SYBR® Reagents  
Created By SS  
Description   
Endogenous Control(s) 36B4  
Instrument Type(s) sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast 
Last Modified Wed May 27 18:04:33 CEST 2009  
Number of Experiments 6  
RQ Confidence Level 95.0  
Reaction Volume 8.0  
Study Name 
Overall TERRA expression in astrocytic brain 
tumours   
Study Type RQ  
Technical Replicate Reference Sample gbm10  
 
 
Flag Name Description Criteria Frequency 
SPIKE Noise spikes The amplification plot contains one or more data points inconsistent with the other points in the plot Spike algorithm result > 1.0 1 
BADROX Bad passive reference signal Passive reference signal is abnormal Bad passive reference algorithm result > 0.6 0 
NOAMP No amplification The sample did not amplify Amplification algorithm result < 0.1 8 
CTFAIL Cт algorithm failed The software cannot calculate Cт.  0 
BLFAIL Baseline algorithm failed The software cannot calculate the best fit baseline for the data.  0 
EXPFAIL Exponential algorithm failed The software cannot identify the exponential region of the amplification plot.  2 
THOLDFAIL Thresholding algorithm failed The software cannot calculate a threshold.  0 
HIGHSD High standard deviation in replicate group Ct standard deviation for the replicate group exceeds the flag setting. Ct standard deviation > 0.5 7 
OUTLIERRG Outlier in replicate group Ct deviates significantly from Ct values in the associated replicate group  5 
NOSIGNAL No signal in well The well produced very low or no fluorescence.  0 
NOISE Noise higher than others in plate The well produced more noise in the amplification plot than other wells in the plate Relative noise > 4.0 7 
OFFSCALE Fluorescence is offscale Fluorescence exceeds the instrument's maximum detectable range for one or more cycles.  0 
AMPNC Amplification in negative control A sequence amplified in a negative control reaction. Cт < 35.0 0 
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Table5.11 QC summary for 2p and 18p TERRA expression study 
 
 
Chemistry Benign 
Created By SYBR® Reagents 
Description SS 
Endogenous Control(s) betaaktin, 36B4 
Instrument Type(s) sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast,  
 sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast, sds7500fast,  
 sds7500fast 
Last Modified Fri Jun 26 18:02:06 CEST 2009 
Number of Experiments 17 
RQ Confidence Level 95.0 
Reaction Volume 8.0 
Study Name 2p and 18p TERRA expression in astrocytic brain tumours 
Study Type RQ 
Technical Replicate Reference Sample GBM10 
  
 
 
Flag Name Description Criteria Frequency 
SPIKE Noise spikes The amplification plot contains one or more data points inconsistent with the other points in the plot Spike algorithm result > 1.0 9 
BADROX Bad passive reference signal Passive reference signal is abnormal  0 
NOAMP No amplification The sample did not amplify Amplification algorithm result < 0.1 56 
CTFAIL Cт algorithm failed The software cannot calculate Cт.  0 
BLFAIL Baseline algorithm failed The software cannot calculate the best fit baseline for the data.  0 
EXPFAIL Exponential algorithm failed The software cannot identify the exponential region of the amplification plot.  32 
THOLDFAIL Thresholding algorithm failed The software cannot calculate a threshold.  0 
HIGHSD High standard deviation in replicate group Ct standard deviation for the replicate group exceeds the flag setting. Ct standard deviation > 0.5 23 
OUTLIERRG Outlier in replicate group Ct deviates significantly from Ct values in the associated replicate group  2 
NOSIGNAL No signal in well The well produced very low or no fluorescence.  0 
NOISE Noise higher than others in plate The well produced more noise in the amplification plot than other wells in the plate Relative noise > 4.0 9 
OFFSCALE Fluorescence is offscale Fluorescence exceeds the instrument's maximum detectable range for one or more cycles.  0 
AMPNC Amplification in negative control A sequence amplified in a negative control reaction. Cт < 35.0 0 
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5.4 Subtelomeric methylation and telomeric transcription  
 
Methylation of CpG islands for specific subtelomeric regions were determined by bisulphite 
allelic sequencing. Genomic DNA was treated with bisulfit for convertion of non-methylated 
C’s into T’s and PCR was performed on 100ng of bisulfite converted DNA using primers and 
conditions as described in Table 4.5 and Table 4.9, respectively. Amplicons were analysed by 
quantitative sequencing to determine the C/T ratios. A selected subset of high grade tumours 
with high and low 2p TERRA expression and low grade tumours with high and low 2p 
TERRA expression was analysed. Primers available for PCR of CpG islands are positioned 
1,400 bp from the chromosomal 2p end and 800 bp from the chromosomal 18p end. 
DNA samples isolated from GBM27 with both the Trizol method and the Maxwell tissue 
DNA purification kit were converted and amplified by PCR, purified and send to Qiagen for 
quantitative sequencing to determine the ratios of non-converted C’s which correspond to 
methylated C’s. The methylation status of the CpG islands from the subtelomeric regions was 
determined of chromosome end 2p and 18p containing 13 and 14 CpG-positions, respectively 
(Figure 5.24 and Table 5.12). The ratios of methylated to non-methylated CpG positions 
analysed did not show differences larger than the variation limit of the method (5%).  
The methylation of CpG positions varies for CpG island of chromosome 2p between 42 and 
100% and demonstrates 90.8% mean methylation. For CpG island of chromosome 18p, 
methylation of CpG positions vary between 45 and 99% and demonstrate 95.8 mean 
methylation.  
 
The information from both sequencings should be identical, but was sometimes missing (in 
case of Maxwell-DNA) or partially available due to problems with the sequencing reaction.  
 
Sequnencing is done by Sanger method so that the Sequencing primers are already bound to 
the fragment, and that the first bases immediately after the sequencing primer can not be 
completely dissolved (peaks can not be separated). Therefore, the first ~ 45 bases (25 by the 
primer, again about 20 because of weak Separation) from any direction are "lost".  
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Table5.12 Sequencing results of bislulfite converted DNA (isolated form Trizol and Chaps 
lysates) 
a) 
low 2p 
TERRA 
 
RQ 
2pTERRA 1 2 3 4 5 6 7 8 9 10 11 12 13 mean+SD median   
T_for 0.3346 n.a. n.a. n.a. n.a. n.a. n.a. 42 96 87 86 96 83 94 83.4 ± 17.6 87 
T_rev  96 97 98* 99 97 91* 80 95 n.a. n.a. n.a. n.a. n.a. 94.1 ± 5.8 96.5 
C_for  n.a. n.a. n.a. n.a. n.a. n.a. 44 98 83 79 100 83 100 83.9 ± 18.3 83 
C_rev  98* 97 99 99 95 91* 83 97 n.a. n.a. n.a. n.a. n.a. 94.9 ± 5.1 97 
DNA isolated from GBM27 was isolated by two different methods (Trizol and Chaps remainders) and bisulfite 
converted.  
T_for … DNA isolated from Trizol and sequenced with primer MP_HC2 FWD (table 4.4) 
T_rev … DNA isolated from Trizol and sequenced with primer MP_HC2 REV (table 4.4) 
C_for … DNA isolated from Chaps and sequenced with primer MP_HC2 FWD (table 4.4) 
C_rev … DNA isolated from Chaps and sequenced with primer MP_HC2 REV (table 4.4) 
 
b) 
Low18p 
TERRA 
 
RQ 
18pTERRA 1 2 3 4 5 6 7 8 9 10 11 12 13 14 mean+SD median 
T_for 0.1429                 
T_rev  45 78 96 95 83 98 97 99 95 90 n.a. n.a. n.a. n.a. 87.6 ± 15.6 95 
C_for  n.a. n.a. n.a. n.a. n.a. 73 98 98 98 70 66 97 99 98 88.6 ± 13.5 98 
C_rev  51 94 94 95 82 96 96 98 99 86 n.a. n.a. n.a. n.a. 89.1 ± 13.7 94.5 
DNA isolated from GBM27 was isolated by two different methods (Trizol and Chaps remainders) and bisulfite 
converted.  
T_for … DNA isolated from Trizol and sequenced with primer MP_HC18 FWD (table 4.4) 
T_rev … DNA isolated from Trizol and sequenced with primer MP_HC18 REV (table 4.4) 
C_for … DNA isolated from Chaps and sequenced with primer MP_HC18 FWD (table 4.4) 
C_rev … DNA isolated from Chaps and sequenced with primer MP_HC18 REV (table 4.4) 
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24 Methylation of CpG islands from the subtelomeric region of chromosome 2p and 18p. 
DNA isolated with the Trizol and Maxwell method were analysed from tumour tissue GBM27. 
Heatmap indicate color code for % of methylated C’s at the respective CpG-position. Circles that are not filled 
indicate that there is a peak from another base in the sequencing chromatogram higher than the peak for the CpG 
and thus the quantity can not be determined accurate. Primers taken for amplification are located proximate 
before the first and after the last CpG-positions.  
(a) Subtelomeric region of chromosome 2p includes 13 CpG positions and  
(b) Subtelomeric region of chromosome 18p includes 14 GpG positions. Lines represent the sequencing 
reactions performed from 5’ and 3’ site of the amplicon. This information from both sequencings should be 
identical, but was sometimes missing (in case of Maxwell-DNA) or partially available due to problems with the 
sequencing reaction as described in the text. 
 
 
 
Subtelomeric  
region of 18p 
GBM27_Maxwell purification
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Next, the subtelomeric chromosome 2p epigenetic state of 5 grade II and III (DA + AA) and 7 
grade IV astrocytomas was determined.  
Figure 5.25a Linking of primers MP_HC2_FWD and MP_HC2_REV to the genomic sequence of 
subtelomeric region of chromosome 2p in CloneManager 9 program. The primer sequence in this figure is the 
not converted sequence, because they are alingned against the non-converted genomic sequence of the 
subtelomeric region of chromosome 2p. 
Line in the lower panel represents sequence of chromosome 2p end ….. Primers for 2pTERRA expression and 
CpG island-specific PCR are shown). 
Figure 5.25b Linking of primers MP_HC18_FWD and MP_HC18_REV to the genomic sequence of 
subtelomeric region of chromosome 2p in CloneManager 9 program (primers for 18pTERRA expression and 
methylation-specific PCR are shown in the lower panel). 
The primer sequence in the upper panel of the figure is the not converted sequence, because they are alingned 
against the non-converted genomic sequence of the subtelomeric region of chromosome 18p. 
 
Specific PCR was first done with primers as described in literature [24] and with converted 
primers (material section, Table 4.4) as those shown for the chromosomal end 2p and 18p in 
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Figure 5.25a and 5.25b, respectively. The positions of the primers for TERRA PCR 
expression assays analyses are located close to the CpG islands as indicated. Lots of the CpG-
positions could not be determined in the sequencing reaction when using the same primers as 
for PCR (Figure 5.24). The quantitative sequencing method of Qiagen needs few base 
positions (15 to 30) before correct sequence information can be obtained. New reverse 
primers extendet at the 5’ end with a spacer sequence and a T7 primer sequence have been 
constructed (see Methods Table 4.4) Converted DNA was amplified with the new and longer 
primers, and by analysing the amplicons by PAGE gel, it can be seen that they produde more 
primer dimers than the original primers (Figure 5.26). 
To circumvent this problem, amplicons with the new and longer reverse primers were purified 
on a 3% agarose gel before sequencing (Figure 5.26b). Pieces of the agarose gel containing 
respective amplicons were cutted out from gel and sent directly to Qiagen for DNA isolation 
from the gel and subsequent bisulfite sequencing. 
a)                                                                      b) 
 
1   2   3   4    5   6    7   8   9  10  11  12  13  14  15    1       2      3       4      5      6      7      8      9     10 
Figure 5.26(a+b) PCR of bisulfite converted DNA 
(a) PAGE-Gel with amplicons for primers MP_HC2 FWD and MP_HC2 REV (as described in materials and 
methods). Length of PCR product is 129 bp. GBM 2 (lane 1), DA 10 (lane 2), GBM 21 (lane 3), DA 11 (lane 4), 
GBM 28 (lane 5+6), GBM 25 (lane 7), NTC (lane 8), 50bp marker (lane 9), GBM 10 (lane 10), GBM 5 (lane 
11), AA 2 (lane 12), AA 3 (lane 13), DA 5 (lane 14), DA 6 (lane 15); 
(b) 50bp Marker (lane 1), chr2 with new primer on Trizol DNA (lane2), chr2 with new primer on Maxwell DNA 
(lane 3), chr18 with new primers on Trizol DNA (lane 4), chr18 with new primers on Quiagen DNA (lane 5), 
non template control for new primers chr2 (lane6), non template control for new primers chr18 (lane7), chr2 with 
original primers on Quiagen DNA (lane8), chr18 with original primers on Trizol DNA (lane9), chr2 with 
original primers on Trizol DNA (lane10) 
New Primers ... pimers (MP_HC2 FWD + MP_HC2_REV_S) and (MP_HC18 FWD + MP_HC18_REV_S) for 
chromosome 2p and chromosome 18p, respectivively 
Chr2 and chr18 … chromosome2p and chromosome18p, respectively 
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a)                                                                    b) 
 
 
 
 
 
 
 
 
 
 
1      2      3      4      5      6     7     8       9         10     11     12   13    14    15   16    17    18 
Figure 5.27(a+b) PCR of bisulfite converted DNA with primers specific for subtelomeric region of 
chromosome 2p.  
(b) 3% agarose gels to purify amplicons produced with pimers MP_HC2_FWD and MP_HC2 REV_S (as 
described in Materials and Methods). Length of amplicon is 156 bp. As a control, product with primers MP_HC2 
FWD and MP_HC2 REV is also loaded on the gel. DA 10 (lane 1), GBM 2 (lane 2), AA 3 (lane 3), DA 6 (lane 
4), GBM 21 (lane 5), DA 11 (lane 6), GBM 25 (lane 7), GBM 28 (lane 8), control with primers MP_HC2 FWD 
and MP_HC2 REV (lane 9), GBM 10 (lane 10), GBM 5 (lane 11), DA 5 (lane 12), λ-Marker (lane 13), KM-HY 
(lane 14), T98G (lane 15), Saos-2 (lane 16), NTC (lane 17), control with primers MP_HC2 FWD and MP_HC2 
REV (lane 18); 
 
Ratios of methylated versus unmethylated were obtained for 12 out of 13 CpG positions in all 
astrocytomas analysed. 
Sequencing results (Table 5.13a+b and shown in Figure 5.28) revealed, that CpG islands in 
subtelomeric region on chromosome 2p are highly methylated and there is little inter-
individual variation across all tested astrocytomas (Average ± SD = 87 ± 5 %) with some light 
methylated (<65%) CpGs. 
Unmethylated CpGs were detected in SAOS-2, an ALT tumour-derived cell line, in contrast 
to dense methylation observed in T98G, a telomerase-positive tumour-derived cell line. 
Analysed epigenetic state did not differ between tissue sample groups of low and high tumour 
grades (P=0.6506) but between groups of low and high 2p TERRA levels (P=0.0127).  
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low 2p 
TERRA 
 
RQ 
2pTERRA 
RQ 
TL 1 2 3 4 5 6 7 8 9 10 11 12 13 mean+SD median   
DA5 0.2369 0.36 89 77 85 93 90 95 93 92 97 90 n.a. 80 96 89.8 91 
DA11 0.7585 8.15 86 65 65 78 73 86 82 92 92 78 n.a. 75 94 80.5 80 
AA3 0.0894 8.90 84 75 83 92 86 83 76 91 86 56 n.a. 79 95 82.2 83.5 
Gbm 2 0.0259 4.75 93 83 73 95 76 92 87 93 95 88 n.a. 72 98 87.1 90 
Gbm21 0.0331 8.97 88 77 85 92 90 93 75 92 80 78 n.a. 83 94 85.6 86.5 
Gbm27 0.3346 1.33 96 97 98 99 97 91 80 95 83 79 100 83 100 83.9 83 
Gbm28 0.1801 5.25 82 76 90 93 90 96 94 94 97 93 n.a. 82 98 90.4 93          
Table 5.13a Methylation of CpG islands in the subtelomeric region of chromosome 2p in samples with high 2p 
TERRA expression. Methylation level is shown for the individual CpG islands and also mean and median of 
methylation of all CpG islands is listed in the table. 
Italic, bold … light methylated CpGp positions 
 
high2p 
TERRA 
 
RQ 
2pTERRA 
RQ 
TL 1 2 3 4 5 6 7 8 9 10 11 12 13 mean+SD median   
DA6 0.8444 82.34 91 76 84 81 63 47 95 87 97 96 n.a. 91 96 83.7 89 
DA10 0.7170 7.74 85 77 87 93 87 93 71 94 76 52 n.a. 77 94 82.2 86 
AA2 0.3075 16.21 96 93 86 96 86 94 96 99 98 100 96 92 99 94.7 96 
Gbm 5 1.1464 8.17 81 78 71 88 84 88 95 93 97 93 n.a. 92 89 87.4 88.5 
Gbm10 1.2572 26.96 85 63 79 92 87 93 58 86 91 85 n.a. 86 95 83.3 86 
Gbm25 0.3415 6.59 89 79 90 94 91 96 93 95 98 95 n.a. 88 97 92.1 93.5 
T98G 0.0218 10.96 99 90 95 93 95 97 99 95 99 n.a. n.a. n.a. n.a. 95.8 95 
SAOS2 0.1134 37.46 n.a. n.a. n.a. n.a. n.a. n.a. 32 28 13 2 3 14 29 17.3 14 
Table 5.13b Methylation of CpG islands in the subtelomeric region of chromosome 2p in samples with high and 
low 2p TERRA expression. Methylation level is shown for the individual CpG islands and also mean and 
median of methylation of all CpG islands is listed in the table. 
Italic, bold … light methylated CpGp positions 
 
 103 
(a) 
                                                           1                    2                 3                  4   5              6 
GTATTGTAGGTGTATAGTTGTATAAGCGTATAGTCGTAAGTCGTTAGGCGCGGAGCGTGGGGG 
           7                             8                     9        10            11              12  13 
TGGCGGGGTGTAGGCGTAGAGACGGACGTTTTCGGGGGCGCGGTATAGAGATAGGTGGAATT 
 
TTAGATTGATTTTTTATAGTGAGTTGTATTA 
 
 
(b) 
                    
 
 
 
 
Figure 5.28 (a+b) Methylation of CpG islands in the subtelomeric region of chromosome 2p.  
(a) Sequence of subtelomeric region of chromosome 2p. 13 CpG islands are included in this region. CpG islands 
are labelled in red and by a serial numbers from 1 to 13.  
(b) Methylation of CpG islands in astrocytoma tissue samples. Samples are splitted into high 2p TERRA 
expressing samples and low 2p TERRA expressing samples. Colours of circles show percentage of methylation 
of individual CpG islands as indicted by the heat map. 
 
Mean methylation of the CpG-island for 2p TERRA was compared between tumour samples 
expressing 2p TERRA at a low and high level. A significant difference could be demonstrated 
with the mean methylation status of all CpG-positions analysed at the CpG-island (Figure 
5.29). High 2p TERRA expressing samples are less methylated, than samples with low 
expression of 2p TERRA. 
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In contrast, there was no significant difference when mean methylation was compared 
between grade II/III and grade IV astrocytic tumour samples (Figure 5.30). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.29 Differences in mean methylation between high and low 2p TERRA expressing tumour 
samples. There is a significant (*) difference in the mean methylation of all 13 CpG islands and the expression 
level of 2p TERRA when testing data with unpaired t-test with Welch´s correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.30 Difference in mean methylation of all 13 CpG islands in grade II/III and grade IV tumour 
samples. The unpaired t-test with Welch´s correction showed no significant difference in the mean methylation 
between low grade tumour samples and high grade tumour samples. The methylation result of the single grade II 
probe is marked by an open circle. 
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Comparing the telomere maintenance mechanism (TMM) used with the methylation of 2p-
subtelomeric region; no correlation was found, neither with telomerase activity nor with 
telomere length. No significant difference in mean methylation was detected when tumours 
with negative and positive telomerase activity or long and short telomeres were tested (Figure 
5.31). 
 
  
Figure 5.31 Comparison with unpaired T-test with Welch´s correction of telomerase activity and telomere 
length status with methylation of subtelomeric region of chromosome 2p 
Median of RQs of telomere length was used for grouping tumours in long and short telomeres. 
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5.5 Comparison with clinical data 
 
For 27 out of 28 (96%) and for 17 out of 18 (94%) patients with high (GBM) and low (AA, 
DA) grade clinical data were available, respectively. 
For correlating survival of patients with diagnosed tumour grade, TL, overall TERRA, 2p 
TERRA and 18p TERRA, the median over all tumour samples was used to classify patients in 
groups with low and high values. The two resulting survival curves were compared to differ 
significantly by the log-rank (Mantel-Cox) test. 
Clinical data demonstrate that 2 (Figure 5.32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.32 Survival of patients compared with tumour gradeII/III und IV!).  
Mean survival GBM … 20.6 months 
Mean survival AA … 49.9 months 
Mean survival DA … > 72 months 
 
Next, survival of patients suffering from low and high grade astrocytomas was compared with 
telomere length. This result shows that patients with longer telomeres survive significantly 
longer (mean survival= >72 months) when compared to patients with short telomeres (mean 
survival=20.2 months) shown in Figure 5.33. 
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Figure 5.33 Correlation of telomere length with survival. Higher telomere lengths show a significantly better 
outcome for patients suffering from astrocytomas. The median of the RQs of telomeres was taken to classify 
long and short telomeres. 
Mean survival for long telomeres … >72 months 
Mean survival for short telomeres … 20.2 months 
 
The correlation between survival of patients and TERRA expression (overall TERRA, 2p 
TERRA and 18p TERRA) and methylation gave following results (Figure 5.34). High 
expression of overall TERRA correlated significantly with a longer survival (mean survival 
high overall TERRA expression>72months and for low overall TERRA expression = 25.9 
months), while 2p TERRA correlated with longer survival only, when the median of low 
grades was used for the classification of patients in groups with low and high 2p TERRA 
expression (mean survival high 2pTERRA expression>72months and for low 2pTERRA 
expression = 29.4 months). 18p TERRA never showed a correlation with survival, leading to 
the conclusion, that not all but some specific TERRA transcripts might be responsible for 
prediction of a longer patient survival.  
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b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.34 (a–c) Kaplan-Meier survival curves for correlation of overall, 2p and 18p TERRA expression with 
survival 
(a) High overall TERRA expression correlates significantly with longer survival, 
     Mean survival for high overall TERRA expression … >72 months 
     Mean survival for low overall TERRA expression … 25.9 months 
(b) high 2p TERRA expression correlates with longer survival,  
     Mean survival for high 2pTERRA expression … >72 months 
     Mean survival for low 2pTERRA expression … 29.4 months 
(c) 18p TERRA expression shows no correlation with survival 
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6 Discussions 
 
Linear chromosomes of eukaryotic cells are capped by telomeres, which protect the ends of 
chromosomes from being recognized by DNA repair mechanism as ds DNA breaks and from 
signalling DNA damage. Telomeres achieve this, by interaction of telomeric DNA and 
telomere associated proteins. In normal human cells, telomeres consist of 4 to 12 kb of ds 
DNA of 5´-TTAGGG-3´ repeats [41], terminating in an ss DNA 3´-overhang of the G-rich 
sequence [42]. 
In this study I have determined the telomere length and the RNA expression of telomeres 
(TERRA molecules) in tumour samples of patients suffering from astrocytic brain tumours 
and in non-tumour tissue obtained from epileptic foci. Beside this in vivo material I analyzed 
in vitro cell lines established from astrocytic brain tumours and from cell line Saos2, derived 
from a primary osteosarcoma. Saos2 is described in the literature as telomerase negative but 
ALT positive cell line [43]. The astrocytoma cell lines analysed all utilize telomerase activity 
as TMM and not ALT (D.Mejri personal communication, data not shown). For measurement 
of telomere length I isolated DNA by two different methods, namely Trizol and Maxwell 
DNA Purification Kit. The amounts I isolated by Trizol method were less, compared to DNA 
isolated with Maxwell DNA Purification Kit. The purity of the isolated DNA by both methods 
was generally in the range of 1.75 – 2.0 (ratio of absorbance at 260 nm to absorbance at 280 
nm). This indicates a low content of protein which could interfere with the following 
analyses. In a first set of experiments, I used Trizol isolated DNA for successful 
determination of telomere length by Real time qPCR. I found that DNA isolated by this 
method is not suitable for TRF analysis, because it was not or only partially digestible by 
restriction enzymes. Kong et al [44] described DNA isolated from rat tissue by Trizol method 
as a high-quality DNA with an average amount of 150 -300 ng/µl and a purity of 1.75 - 1.95. I 
did not found any published data for astrocytomas after extensive search in the literature. In a 
second set of experiments, I used for TRF analysis DNA isolated by the Maxwell DNA 
Purification Kit. The DNA was directly isolated from tissue samples or cell pellets, or 
alternatively from cells after mild protein extraction with Chaps detergence from the 
remainders as described by Henson et al [30]. This DNA from high quality and purity was 
completely digestible and therefore suitable for telomere length determination by TRF 
analyses. Next, I compared the two basically different methods PCR and TRF analyse for 
measuring the telomere length in vivo and in vitro. I found a weak but significant correlation 
between the two methods (P=0.427; p=0.0212). This allowed me to use the more simple 
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method PCR to determine the absolute telomere length of tumour samples, similar as 
measured on blood cells published by O´Callaghan [32]. Furthermore, all DNA from tissue 
samples and cell lines isolated by the Trizol method was adaptable. Relative T/S ratios of the 
PCR results were converted to absolute mean TRF telomere lengths in kb using linear 
interpolation. 
My results of telomere length measurement demonstrate a mean telomere length over 17 kb 
for diffuse astrocytoma (DA) and anaplastic astrocytoma (AA), but not in glioblastoma 
multiforme (GBMs). This indicates a higher content of ALT positive tumours in low grade 
tumours as compared to GBM. 
Hakin et al [39] defined a telomere length of over 17 kb as a key feature of ALT. Le et al [45] 
detected telomerase activity in 33% of DA, 45% of AA and 89% of GBM, indicating a higher 
percentage of low grade tumours using the ALT mechanism compared to GBMs. Thus my 
measured telomere length in astrocytomas correlates with data from literature [39, 45]. 
I quantified the expression of overall TERRA and chromosome specific TERRA for 
chromosome 2p and 18p. I found the expression of overall TERRA significantly decreased in 
GBM compared to AA and DA. Astrocytoma cell lines contained TERRA levels found as in 
GBM, the ALT cell line as in DA. Consistent with these results, Schoeftner and Blasco [20] 
found TERRA significantly downregulated in advanced stages of different human types of 
cancer compared to normal tissue. This suggests that down regulation of TERRA is a general 
mechanism by disease progression and is associated with undifferentiated cell stages.  
The expression of specific chromosome 2p and chromosome 18p TERRA was measured by 
Real Time PCR with self-designed primers within the sub-telomeric region. In contrast to 
overall TERRA, the expression found for 2p and 18p TERRA was not significantly altered 
and depending on tumour grade. I could not find any results in the literature for quantification 
of chromosome specific TERRA expression. Why chromosome specific TERRA levels do not 
reflect overall TERRA remains to be further investigated. 
For the subtelomeric region of chromosome 2p I determined the methylation state of CpGs as 
described [24]. When comparing tumours showing a high 2p TERRA expression with 
tumours of low TERRA level the average methylation was significantly decreased. Thus 
methylation correlates inversely with TERRA expression. Like 2p TERRA expression 
methylation state also did not show a significant change with grade of the tumour. 
Methylation in CpG dinucleotides is a well known marker for transcriptional silencing, and 
sequences maintained as heterchromation are usually heavily methylated [46]. 
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By analyzing my data I found a strong positive correlation between the telomere length and 
the overall TERRA expression. This finding is supported by Ng et al [24]. They report a 
reduced TERRA expression in telomerase-positive cells compared to normal and ALT cells. 
In contrast to cells with telomerase activity, ALT cells like the SAOS-2 cell line I analysed, 
have longer telomeres and a higher content of TERRA. TERRA oligos were shown to inhibit 
telomerase activity [28]. Thus, TERRA silencing could maybe important in order to facilitate 
telomerase activity at telomeres. 
I compared my result with patient data like the diagnosis (grade of the tumour) and the 
survival of patients. Patients with the diagnoses DA and AA survived significantly longer 
compared to patients with GBMs (logrank test for trend p=0.0009). Patients suffering from 
GBM have mean survival of 20.6 months, AA 49.9 months and DA > 72 months Fitting 
published data [2] with a mean survival GBM patients of <12 months, AA 24 - 60 months and 
DA 44 - 96 months. 
Long telomeres correlate significant with a longer survival of patients (p=0.0137). Patients 
with long telomeres showed a mean survival of over 72 month, compared to a mean survival 
of 20.2 month for patients with short telomeres. Also a high expression of overall TERRA 
correlates significantly with a better outcome (p=0.0346). Mean survival for high and low 
overall TERRA expression is > 72 months and 25.9 months, respectively. Both, high telomere 
length and high expression of TERRA are both features of ALT [24].  
This findings are supported by published data [30], that ALT positive tumours have a better 
outcome than telomerase positive tumours.  
In addition to overall TERRA also low 2p TERRA expression correlates with a poor outcome 
(p=0.0384). Mean survival for patients with high and low 2pTERRA expression are >72 
months and 29.4 months, respectively. 18p TERRA did not show to correlate with the 
prognosis (p=0.8272). After extensive search I found no published data for the influence of 
chromosome specific TERRA on the survival of patients. 
Maybe TERRA could be a promising candidate a prognostic and potentially prognostic 
marker in astrocytomas. To fully understand mechanisms and functions of TERRA, futher 
studies would be needfull. 
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